The significance of CTLA-4(cytotoxic T-lymphocyte associated protein 4) gene polymorphism in susceptibility to systemic lupus erythematosus. by Divya, M
 THE SIGNIFICANCE OF CTLA-4  (CYTOTOXIC  
T-LYMPHOCYTE ASSOCIATED PROTEIN 4)  
GENE POLYMORPHISM IN SUSCEPTIBILITY  
TO SYSTEMIC LUPUS ERYTHEMATOSUS  
   
 
Dissertation submitted for 
 
M.D. BIOCHEMISTRY BRANCH – XIII 
DEGREE EXAMINATION 
 
 
 
            THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY 
CHENNAI – 600 032 
TAMILNADU  
 
 
APRIL 2016 
 BONAFIDE CERTIFICATE 
 
 This to certify that this dissertation work entitled “THE 
SIGNIFICANCE OF CTLA-4(CYTOTOXIC T-LYMPHOCYTE 
ASSOCIATED PROTEIN 4) GENE POLYMORPHISM IN 
SUSCEPTIBILITY TO SYSTEMIC LUPUS ERYTHEMATOSUS”  is the 
original bonafide work done by Dr.M.DIVYA, Post Graduate Student, 
Institute of Biochemistry, Madras Medical College, Chennai under our direct 
supervision and guidance. 
 
 
 
 
 
Prof. Dr.K.PRAMILA, MD., (Guide) 
Professor and Head, 
Institute of child Health, 
Madras Medical College 
Chennai-600 003.     
Prof. Dr. K.Ramadevi. MD., 
Director & Professor, 
Institute of Biochemistry 
Madras Medical College 
Chennai-600 003.     
 
 
 
 
Dean 
Madras Medical College and 
Rajiv Gandhi Government General Hospital, 
Chennai - 600 003. 
 
 
DECLARATION 
 
 
 I, Dr.M.DIVYA , Post Graduate , Institute of Biochemistry, Madras 
Medical College, solemnly declare that the dissertation titled “THE 
SIGNIFICANCE OF CTLA-4(CYTOTOXIC T-LYMPHOCYTE 
ASSOCIATED PROTEIN 4) GENE POLYMORPHISM IN 
SUSCEPTIBILITY TO SYSTEMIC LUPUS ERYTHEMATOSUS”  is the 
bonafide work done by me at Institute of Biochemistry, Madras Medical 
College under the expert guidance and supervision of Prof.Dr.K.PRAMILA, 
M.D., Professor & Head, Institute of Child Health, Madras Medical College. 
The dissertation is submitted to the Tamil Nadu Dr.M.G.R Medical University 
towards partial fulfillment of requirement for the award of M.D., Degree 
(Branch XIII) in Biochemistry. 
 
 
 
 
 
Place: Chennai 
 
Date:                               Dr.M.DIVYA 
 
 
 
 
 
 
 
 
 
SPECIAL ACKNOWLEDGEMENT 
 
 
The author gratefully acknowledges and sincerely thanks Professor 
Dr.R.VIMALA, M.D., Dean, Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai, for granting her permission to utilize 
the facilities of this Institution for the study. 
ACKNOWLEDGEMENT 
              I like to express my profound gratitude towards Dr. K. RAMADEVI, 
M.D., Director and professor, Institute of Biochemistry, Madras Medical 
College, Chennai, for allowing me to utilize the facilities in department 
(molecular biology lab and centralized 105 lab) for the dissertation work as 
well as for her able and expertise guidance.  
 
 I sincerely thank my guide Dr. K. PRAMILA, M.D., Professor and 
Head, Department of Biochemistry, Institute of Child Health, Egmore, 
Chennai, for her persistent guidance and encouragement throughout the work. I 
also like to thank her for allowing me to utilize the facilities in ICH for the 
research work 
 
 I am extremely thankful to Dr. RAJESWARI, Professor and HOD, 
Department of Rheumatology, Rajiv Gandhi Govt. General Hospital, Chennai 
for granting permission to obtain blood samples from the patients. 
 
 . I like to thank Dr. V. ANANTHAN, Assistant professor, Institute of 
Biochemistry, Madras Medical College for sharing his profound practical and 
theoretical knowledge which makes the study possible as well as for his help in 
statistical work.  
 
 I also like to thank Dr. C. SHANMUGAPRIYA, Assistant professor, 
Institute of Biochemistry, Madras Medical College for her clear 
troubleshooting ideas.  
 
 I like to thank Dr. SIVA, Assistant professor, Institute of Biochemistry, 
Madras Medical College for his guidance in operating instruments in molecular 
biology lab.  
 
 I also like to express my immense gratitude towards Additional 
professor DR.R.CHITRAA,M.D., Associate professors 
DR.V.AMUDHAVALLI, DR. S. SUMATHI, DR. V.K. RAMADESIKAN 
and the Assistant professors DR.V.G.KARPAGHAVALLI, DR. MYTHILI, 
DR. SUDHA PRESANNA and DR. MENAKA SHANTHI for their 
encouragement and support for the work. I like to thank my colleagues 
Dr.Geetha, Dr.Nirmaladevi, Dr.Ananthi for their sincere support and help.  
I like to thank Mr.R.Ravanan D. Ramanujam, for his help in statistical 
analysis all through the study.  
 
 I am also indebted to the innumerable persons who contributed their 
blood samples for the study. Finally I like to thank my family for their moral 
support.  
 
                     
 
 
CONTENTS 
 
SI. 
NO TITLE PAGE No. 
1 INTRODUCTION 1 
2 REVIEW OF LITERATURE 5 
3 AIM OF THE STUDY 47 
4 MATERIALS & METHODS 48 
5 STATISTICAL ANALYSIS 62 
6 RESULTS 63 
7 DISCUSSION 74 
8 CONCLUSION 78 
9 LIMITATIONS OF THE STUDY  79 
10 FUTURE SCOPE OF THE STUDY 80 
11 BIBILIOGRAPHY  
12 ANNEXURES  
         
 
ABBREVIATION 
 
1. CTLA-4   - Cytotoxic T Lymphocyte Antigen 4 
a) sCTLA-4   - soluble CTLA4 protein 
b) (m)CTLA-4 - membrane CTLA4 protein 
2. SLE           - Systemic Lupus erythematosus 
3. a. ARMS PCR - Amplification Refractory mutation system 
b. T-ARMS PCR- Tetra primer ARMS PCR 
4. ACR   - American college for Rheumatology 
5. BAFF  - B-cell Activation factor  
6. BANK 1 gene - B Cell scaffold protein with ankyrin repeats                   
7. BLK gene - B Lymphocyte specific tyrosine kinase                            
8. CRP  - C- reactive protein  
9. DNAMT1 - DNA methyltransferase 1 
10. FCG2A/ FCG3A - Fc gamma receptor IIa / Fc gamma receptor IIIa  
11. GAD 45 alpha  - Growth arrest and DNA damage induced 45 alpha. 
12. GWAS   - Genome wide association study 
13. ICOS    - Inducible Costimulator  
14. IRF 5      - Interferon regulatory factor 5  
15. ISN/RPS   - International Society of Nephrology /  
    Renal Pathology Society  
16. ITGAM   - Integrin αM                                                                         
17. LAT protein  - Linker for activation of T cells 
18. LRR  - Leucine rich repeats 
19. MDRD    - Modification of diet in renal disease  
20. NPSLE   - Neuropsychiatric systemic lupus erythematosus 
21. pDC          - Plasmacytoid dendritic cells 
22. PDCD1    - Programmed cell death 1  
23. PP2A  - Protein Phosphatase 2A 
24. PTPN22   - Protein tyrosine phosphatase, non-receptor type 22  
25. SEB   - Staphylococcal enterotoxin B    
26. SHP-2   - Src Homology Phosphatase 2 
27. SNP   - Single nucleotide Polymorphism 
28. STAT 4  - Signal transducer and activator of transcription  
    factor 4   
29. TAE   - Tris acetate EDTA buffer 
30. TIR  - Toll/IL-1 receptor 
31. TLR   - Toll Like Receptors 
32.  TNFAIP3 - Tumor necrosis factor- induced protein 3       
33. TNIP1  - TNFAIP3 interacting protein 1                                        
34. Tregs cells   - T regulatory cells 
35. TREX 1  - 3-prime repair exonuclease 1  
36. UTR  - Untranslated region  
THE SIGNIFICANCE OF CTLA-4(CYTOTOXIC T-LYMPHOCYTE 
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ABSTRACT 
INTRODUCTION: 
CTLA4 protein is expressed on the surface of activated T cells, exhibiting a 
negative regulatory role. This protein along with CD28, a positive regulator of T cells 
maintains immune system homeostasis. Polymorphism in CTLA4 gene leads to 
reduced surface expression of CTLA4 protein, resulting T cells become overactive 
against self-antigens, increasing the susceptibility of Systemic Lupus Erythematosus. 
 
OBJECTIVE: 
 To assess frequency of  single nucleotide polymorphism in CTLA4 gene 
among cases/controls, 
  To analyze effect of  polymorphism over protein and disease expression 
 
MATERIALS AND METHODS: 
             CTLA4 genotype (A/G) of 100 known SLE patients was compared with 100 
matched healthy controls. Genotypic expression was correlated to level of CTLA4 
protein and expression of disease. Genotype of patients &controls was detected by 
ARMS PCR, Level of protein measured by ELISA. 
  
 
RESULTS: 
 The genotype distribution is in Hardy Weinberg equilibrium. (Chi square = 
0.54   P =0.7). The frequency of CTLA4 +49 GG genotype is higher in cases than 
controls. The level of soluble fragment of CTLA-4 protein is significantly higher in 
cases compared to controls. Positive correlation exists between CTLA4 protein levels 
and GG genotype (p <0.001).  GG genotype individual have comparatively younger 
age of onset of disease. 
 
CONCLUSION: 
          Transition from A to G allele at 49th position in exon1 of CTLA4 gene will 
result in exchange of alanine for Threonine. There is altered intracellular trafficking, 
surface expression of the protein gets reduced and plasma level gets elevated, 
increasing susceptibility to SLE. Hence G allele in exon1 of CTLA4 gene will 
increase risk of SLE. 
 
KEY WORDS: 
 Systemic lupus Erythematosus, Cytotoxic T Lymphocyte antigen 4, ARMS 
PCR, Single nucleotide polymorphism. 
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INTRODUCTION 
 
 Systemic lupus erythematosus is one of the most significant diseases in 
the field of medicine. The disease predominantly targets young women of 
reproductive age group and has the potential to cause significant physical 
disfigurement, extensive morbidity, with occasional mortality. Identification of 
immunological contributors to lupus had been the focus of intense research in 
the initial era. But the recent efforts, apart from supporting the central role of 
immune system in disease pathogenesis have also defined the genetic variations 
that underlie susceptibility to lupus. So the view on lupus pathology is 
extended beyond autoantibodies to include the contribution by several 
candidate genes. Single nucleotide polymorphisms play crucial role in the 
disease pathogenesis and progression. The recent advances concentrated on 
genetic variations have provided important insights into how the intersection of 
genetic variations and environmental triggers amplifies immune system 
activation and target organ vulnerability to generate the clinical manifestations 
of lupus.  
 
The genetic contribution to SLE can be supported by assessing the 
concordance rate of SLE among mono and dizygotic twins. Monozygotic twins 
have 30% concordance of SLE whereas the concordance rate is only 3% for 
dizygotic twins (10 times higher rate of concordance)1.  The identification of 
single nucleotide polymorphism in diagnosis of SLE has been markedly 
elevated in recent years. Two major collaborative genome wide association 
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studies, one organized by SLE genetics (SLEGEN) and other by Genentech, 
identified nine new genes associated with SLE2,3 . Both the above studies have 
arrived at a common conclusion that, lupus associated genes will encode a 
specific protein necessary for the proper functioning of immune system. 
Defective gene leads to the synthesis of a defective protein which in turn is the 
etiology behind malfunctioning of the immune system. The present study also 
goes with the conclusion arrived by the previous studies, but introduces a 
different genetic loci, 2q33.2 of CTLA-4 gene in the disease pathogenesis. The 
product of this gene is called CTLA-4 protein which is involved in the down-
regulation of T-cell activity. The study briefly discusses the effect of CTLA-4 
gene polymorphism over the level of encoded CTLA-4 protein and its possible 
role in clinical manifestation of .the disease. 
 
 The initiation of T cell activation requires two separate signals, a 
primary signal presented by MHC class of molecules and a secondary non-
specific signal generated by the co-stimulatory molecules4,5. The secondary co-
stimulatory signal is the result of interaction between CD-28 molecules on T 
cells with the B7 family of molecules, B7-1 (CD-80) and B7-2 (CD-86) on the 
surface of antigen-presenting cells (APCs) 6,7. A molecule that is a structural 
homolog of CD-28, cytotoxic T lymphocyte associated antigen-4 (CTLA 4) is 
also expressed on the surface of T cells. In contrast to CD-28, CTLA-4 has a 
negative regulatory role on T cells8,9. Both CD-28 and CTLA-4 molecules will 
bind to same ligands on the surface of antigen presenting cells, CD-80 and CD-
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86. But the affinity of CTLA-4 for CD-80 and CD-86 is 20 to 50 times higher 
than that of CD-28.                    
 
 CD-28/B7 co-stimulation is the up regulator for T cell responses 
whereas CTLA-4/B7 is the down regulator for the development and 
maintenance of T cells responses10. Thus CTLA4 acts as the second receptor 
for B711.  This CTLA-4 mediated negative regulation on T cells is necessary for 
the induction of antigen specific tolerance12. Elimination of this tolerance by 
specific pathological conditions is responsible for the development of various 
autoimmune diseases.  
 
 The CTLA4 gene of non activated T cells when subjected to PCR 
produces two different amplicons of size 650 and 550 bp13. This is due to the 
alternate splicing of CTLA-4 mRNA, which will generate a soluble form of 
CTLA-4 molecule called sCTLA-4. Normal human will have low levels of 
sCTLA-4. The patients with SLE have increased sCTLA-4 expression on the 
surface of T cells14. sCTLA-4 molecule has the role in pathogenesis of this 
autoimmune condition15. This soluble fragment of CTLA-4 molecule in low 
levels is responsible for inhibiting the activation of T cells. This is 
accomplished by blocking the interaction between CD-28 and CD-80/86. On 
the other hand the same soluble CTLA 4 molecule on higher level will inhibit 
the binding of membrane CTLA 4 with CD-80/86. This in turn will reduce the 
inhibitory signal to the T cells. Due to this reduced inhibitory effect there will 
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be failed inhibition of autoreactive T cell that is responsible for the 
pathogenesis of SLE.  
 
 This case-control study is sought to determine the frequency of CTLA-4 
exon 1 polymorphism (+49A/G) among SLE patients and also to correlate it 
with sCTLA-4 protein levels and disease pathogenesis. 
 
FUNCTIONAL RELEVANCE OF GENE POLYMORPHISM AND THE 
DISEASE EXPRESSION 
 
  
AUTOIMMUNITY IN SLE
Overactivity of 'T' cells to the native antigens
(m)CTLA-4 is reduced & sCTLA-4 gets elevated
Expression of CTLA-4 protein on the cell surface gets reduced and soluble 
fragment in plasme gets elvated
Altered intracellular trafficking of CTLA-4 protein
Altered CTLA-4 protein (Aminoacid change in leader peptide sequence)
CTLA-4 gene polymorphism (Normal 'A' allele is replaced by risk 'G' allele)
Review of Literature 
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REVIEW OF LITERATURE 
 
 Systemic Lupus erythematosus is the prototypic systemic auto-immune 
disease characterized by diverse multisystem involvement and the production 
of array of antibodies. Clinical manifestations of the disease is quite variable 
among individual patients, ranging from mild joint and skin involvement to 
severe life threatening internal organ damage16 
 
EPIDEMIOLOGY: 
 The Prevalence of SLE has a wide variation among various population 
groups and sub groups ranging from 20 to 240 per 100,000 persons17. This 
wide variation in prevalence is due to the fact that both geographical location 
and racial features has significant effect on SLE prevalence. There is 
comparatively higher prevalence of SLE among Asians, Afro-Americans, and 
Hispanic Americans compared with Americans of European descent in the US. 
Due to improved detection of the earlier stage of the disease, many cases of 
SLE that have earlier gone undetected have now come to limelight and adds to 
the disease load. So due to this improved rate of detection the incidence rate of 
SLE has increased four-fold in last 60 years18. Estimated incidence rates are in 
average of 1 to 10 per 100,000 person-years17,19. The prevalence is also higher 
among Asian Indians compared with Caucasians in Great Britain. In European 
countries compared to Indo-Asians, Caucasians are having 2-3 times lower 
prevalence rate for SLE21. There is 2-3 fold higher prevalence of SLE among 
Asians/Hispanics compared with white populations20.  
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 SLE predominantly affects the female population and majority of 
females are in the reproductive age group. The female to male ratio varies with 
the age, the ratio being 8:1 in children, 10 to 15:1 in adults and 3:1 in elderly 
population 21. Nearly three fourth of the individuals affected with SLE are in 
the age group of 15-64 years23. SLE can also affect the pediatric age group 
(<15 years of age) and most of the affected children are Africo-American22. 
SLE in pediatric age group and also in male population will be having a more 
severe progression. The true geographic, racial, and temporal differences in 
SLE incidence and prevalence may yield important clues to the etiology of 
disease. 23 
ETIOPATHOGENESIS: 
 Multiple etiological factors cross-link that leads to the development of 
disease. It is very difficult to define a specific etiological agent for the disease. 
Apart from genetic/epigenetic factors that plays a crucial role in the 
development of the disease multiple ethnic, geographical, immune regulatory, 
hormonal and many other environmental factors are also responsible for the 
manifestation of the disease 24.SLE patients exhibit an abnormality in estrogen 
metabolism, there is increased 16α hydroxylation of estrone in SLE patients to 
form 16α hydroxyoestrone25.  Nurses’ Health Study which has been done in a 
large cohort of nurses has proved that, there is increased risk of SLE associated 
with the use of oral contraceptive pills and Hormone replacement therapy26,27. 
Exogenous administration of estrogen will exacerbate the existing lupus.28, 29 
The major factor responsible for the pathogenesis of SLE is, the self- reactive T 
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cells, which interact with B cells and promotes B cell differentiation and 
production of antibodies in SLE. Pathogenic autoantibodies to DNA are 
frequently associated with autoantibodies to chromatin-associated proteins such 
as histones or the. The serum examination in lupus patients has shown 
antibodies complexed to DNA or DNA binding proteins like histones and Ku 
(p70/p80) antigens.30. Although Lupus pathology does depend on immune 
complex formation and deposition, subsequent investigations identified 
virtually all cellular components and even many soluble immune system 
products, that acts as contributors to immune system dysfunction in the disease 
16. One such soluble immune system product to be responsible for pathogenesis 
of SLE is soluble fragment of CTLA-4 (sCTLA-4) protein whose production is 
increased due to alternate splicing of CTLA-4 mRNA. Various other 
deficiencies in T cell function such as defective production of typical T cell 
cytokine interleukin-2 or defective IL-2 receptor have also been described to 
play a role in autoimmunity in SLE 31.   
 
CONTRIBUTORS OF SYSTEMIC LUPUS ERYTHEMATOSUS 
PATHOGENESIS: 
 The genetic profile of an individual is a major factor in determining the 
susceptibility to the development of disease. Many disease associated genetic 
variants are identified and these variants are either associated with increased 
production of stimulatory nucleic acids or their impaired clearance. Products of 
innate immune response like type I interferons are also produced in increased 
amounts. There is an altered threshold of activation or efficiency of signaling 
8 
 
of cells of the adaptive immune response. Multiple genetic variants along with 
the environmental triggers establish a state of immune activation that leads to 
the development of autoimmune disease. But in rare cases a single mutation in 
genes that are the critical regulators of immune system activation are sufficient 
to the development of altered immune status and the development of 
autoimmunity.  
 
 Plasmacytoid dendritic cells (pDCs) are responsible for the production 
of Type 1 interferons. These cells are activated by intracellular nucleic acids or 
by exogenous triggers like virus or some other debris. The activation of pDCs 
might be the contributing factor responsible for the initiation and progression 
of disease. The production of IFN-α has a numerous effects on the cells of 
immune system, there will be augmented antigen presenting capacity of 
myeloid dendritic cells and this in turn will activate self reactive T cells and 
this leads to the differentiation of B cells and production of pathogenic 
antibodies. The increased expression of CD-154 on the surface of activated T 
cells associated with increased release of interleukin-21 will act as stimulus for 
B cells to differentiate into antibody producing plasma cells. There is also 
increased production of B cell activation factor (BAFF), which is needed for 
survival and differentiation of B cells 29. There is increased autoantibody 
production from B cells and increased immune complex deposition in the 
vicinity of the blood vessels. This deposited immune complex will promote the 
complement activation, inflammation and tissue damage and also IFN-α will 
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stimulate endothelial cells which is associated with poor vascular repair and 
sclerosis. 
 
 In spite of these above gains in elucidating the pathogenesis of SLE, the 
environmental triggers and genetic susceptibility factors that lead to the 
initiation of autoimmunity remain largely undefined in majority of the SLE 
patients. The major environmental trigger being identified to be responsible for 
pathogenesis of SLE is ultraviolet light mediated DNA damage and 
modification of DNA methylation that renders self-nucleic acid stimulatory to 
the immune system. 
 
 In healthy individuals, dendritic cells and macrophages are involved in 
the presentation of antigens to T cells. In the process auto-reactive T cells will 
be inactivated. Fc receptors of low affinity, complement receptors of low 
density, and genetic or acquired deficiency of complement factors diminish the 
capacity of the immune system of patients with lupus to scavenge immune 
complexes and apoptotic cell debris. These factors, along with an increased 
load of apoptotic cells, overload the immune system with auto-antigens. The 
increased load in a susceptible individual leads to the development of 
autoantibodies. These autoantibodies opsonize apoptotic cells, which favors an 
inflammatory manifestation. Additionally, they form immune complexes that 
stimulate antigen-presenting cells, thus creating a vicious circle (FIGURE 1). 
  
  
 
 
FIGURE 1 
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I. GENETIC CONTRIBUTORS TO LUPUS PATHOGENESIS 
 There are many evidences that document the importance of genetic 
factors, contributing to SLE. For example, there is a strong familial clustering 
of the disease, with 10% to 12% of SLE patients having affected first-degree 
relatives 32. Data also suggests that there is 10 times higher concordance of 
clinical lupus among monozygotic twins compared to dizygotic twins, although 
the highest concordance rate is still only 57% 16. 
 
Genetic variants associated with systemic lupus erythematosus: 
 Homozygous deficiency of early complement components (C2, C4A, 
C4B)- 5 to 10 fold increased risk 33 
 Major Histocompatibility complex genes Associated with SLE: 16 
o HLA DR 2/ HLA DR 3 – 2 to 5 fold increased risk34 
o HLA DR2/DRX   -  Associated with anti-Sm antibodies 
o HLA DR3/DRX -  Associated with anti-Ro and anti-La antibodies 
o HLADR2/DR3 - Associated with anti-Ro, anti-La, anti-Sm and 
anti-ds DNA Ab    
o HLADR3/DR3 - Associated with anti-Sm antibodies 
 Non- MHC genes associated with SLE16 
o Homozygous deficiency of C1q 
 Association based on linkage studies16 
o Fc gamma receptor IIa (FCG2A) 34 
o Fc gamma receptor IIIa (FCG3A) 
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o Programmed cell death 1 (PDCD1) 
 Association based on candidate gene studies  16  
o C- reactive protein (CRP) 
o Interferon regulatory factor 5 (IRF 5) 36 
o Interleukin- 10 (IL- 10) 
o Protein tyrosine phosphatase 22 (PTPN22) 
 Association confirmed by genome wide association studies 16 
o B Cell scaffold protein with ankyrin repeats - BANK 1 gene37 
o B Lymphocyte specific tyrosine kinase  - BLK gene38 
o Tumor necrosis factor- induced protein 3  - TNFAIP3 
o TNFAIP3 interacting protein 1    - TNIP1 
o Signal transducer and activator of transcription factor 4 – STAT 4 
o 3-prime repair exonuclease 1   -  TREX 1 
o Integrin Αm      -   ITGAM 
 
              SLE associated genes are involved in the generation of self-antigens, 
innate immune system activation and also activation of adaptive immune 
system. The deficiency of the genes responsible for the synthesis of 
complement components like C2, C4 and C1q can also lead to lupus 
pathogenesis. When this complement components are defective there will be 
defective clearance of cellular debris, in other words there will be increased 
accumulation of nuclear debris. This increased nuclear debris will act as self-
antigens and stimulate self- reactive T cells that further leads to autoimmunity. 
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 Although GWAS has identified a significant statistical association 
between variations in genes sequences with diagnosis of SLE, the functional 
consequence of these variations has not yet been studied. The gene that has 
been best studied to understand the impact of lupus associated variants on 
immune cell function are the genes involved in the production of Type I IFN. 
The risk alleles IRF5 and IRF7 are associated with increased serum type I IFN 
activity in those patients who demonstrate autoantibodies targeting DNA or 
RNA associated proteins 39, 40. 
 
II. FEMALE PREDOMINANCE OF SYSTEMIC LUPUS 
ERYTHEMATOSUS: 
 
 SLE has a dramatic female preponderance in the ratio of 9:141. 
Hormonal factors play a crucial role in immune system activation which is 
responsible for the female preponderance of the disease; Elevated levels of 
estrogen and prolactin will promote the survival and activation of autoreactive 
B cells42. Estrogens will modulate the activation of lymphocytes and prolactin 
has also been shown expressed at increased levels in serum of lupus patients. 
There is a positive relationship between early menarche and SLE, and 
breastfeeding mothers have lower risk of SLE43. Men with Klienfelters 
syndrome, characterized by a 47XXXY genotype has 14 fold increased risk of 
SLE compared to men without SLE 44. These data suggest that the dose effect 
of X chromosome gene is a possible risk factor for development of SLE. The 
disease has the typical occurrence during the child-bearing age group, after 
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menarche and before menopause. Also there exists a positive correlation 
between early menarche and SLE. The above observations that, increased risk 
of SLE among women who had early menarche and who had not breast fed had 
led to the hypothesis that factors related to   ovulation can contribute to lupus 
pathogenesis. 
 
III. ENVIRONMENTAL TRIGGERS OF LUPUS: 
 There is a higher level concordance of SLE among monozygotic twins 
that ranges from 25-50%45, which provides evidence to the fact that 
environmental factors and stochastic events contribute to the development of 
SLE in an individual. There are two well known environmental triggers that 
contribute to the pathogenesis of SLE, that are UV radiations and certain drugs. 
Ultraviolet rays act on the skin cells, breaks the DNA that ultimately leads to 
altered gene expression. The end result is the apoptotic or necrotic cell death. 
The impaired clearance of these apoptotic cells is one of the factors leading to 
the development of UVB induced skin lesions in lupus patients 46. The likely 
mechanism for the development of drug induced lupus is that there will be 
altered DNA methylation47. Socioeconomic status plays a role in progression of 
SLE, patients of low socioeconomic status have poor access to health care 
hence more severe will be the disease progression48. There are also many 
epidemiological studies that have shown the higher prevalence of EBV antigen 
specific antibodies in children with SLE. A study among military cohort has 
supported the fact that higher level of EBV viral load is associated with greater 
disease pathogenesis49. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2: STRUCTURE OF TOLL LIKE RECEPTORS 
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IV. INNATE IMMUNE SYSTEM ACTIVATION IN SLE: 
 The discovery of TLRs and elucidation of the central role of innate 
immune system in the regulation of acquired immune system has opened new 
insights into the disease pathogenesis. TLRs are classified as type I 
transmembrane proteins that are characterized by an extracellular domain, a 
transmembrane domain and a cytoplasmic tail. (FIGURE 2) 
 
 The extracellular domain will be containing leucine rich repeats (LRRs). 
The cytoplasmic domain will be containing Toll/IL-1 receptor (TIR) domain, 
which initiate a signaling cascade to promote immune response50 
 
The direct pathogenic role of nucleic acid complexed to immunoglobulins in 
lupus are proved by studies based on  
 nucleic acid sensitive TLRs and  
 nucleic acid independent TLR-s 
that are responsible for the production of Type I interferons and other 
proinflammatory mediators. In the peripheral blood cell of the lupus patients, 
there will be broad expression of type I IFN inducible genes and is referred to 
as “IFN signature”51,52,53. These studies points towards innate immune system 
as significant factor contributing to lupus pathogenesis. 
 
 In summary, the important mechanism for lupus pathogenesis is the 
combination of increased generation of modified nuclear material with 
associated impaired clearance of this nuclear material. Recent attention is 
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focused towards microparticles, that are very small membrane-enclosed 
particles released by activated and dying cells, has generated a data 
demonstrating binding of these antigens by several autoantibodies in SLE 
patients54. The deficiency of complement components C1q, C2 and C4 is also 
strongly associated with SLE. This is because C1q and other complement 
components are necessary for the clearance of apoptotic debris in SLE55. Many 
newer diagnostic as well as therapeutic modalities based on regulating the 
complement activity have already been postulated for SLE56. 
 
V. ADAPTIVE IMMUNE SYSTEM ALTERATIONS IN SLE: 
 CD4 +T cells produce helper signal to B cells that drive the B cell 
differentiation and production of autoantibodies. Hence, CD4 + T cells are 
absolutely essential in the pathogenesis of lupus. Many systematic studies done 
on T cells of SLE patients have concluded that defect or possible alterations in 
T cell signaling pathways, release of various cytokines, cellular proliferation, 
and defect in regulatory functions have possible roles in SLE57. Studies of 
lupus T cells have also given an interesting observation of global epigenetic 
alterations of lupus genome which results in autoimmunity. On treating mouse 
and human T cells with azacytidine there is resultant increased expression of 
the lymphocyte function antigen-1 (LFA1; CD11a) adhesion molecule and 
associated enhanced proliferative responses to self-non–T cells58. Ligation of T 
cell receptors and T cell activation results in increased intracellular calcium 
levels, hyperpolarization of mitochondria in T cells59. Individuals of HLA 8.1 
haplotype have characteristic low IL-2 production60. BAFF is survival factor 
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for B cells and is a TNF family member. BAFF expressed by many different 
cell types binds to BAFF receptors that are expressed on the surface of cells 
during development. Many in vitro experiments have been conducted that 
supported the possible role of cytokines such as IL-21 and B lymphocyte 
stimulator (BLys) / B cell activating factor (BAFF) and TLR ligands that 
activate the B cells to produce antibodies ,Out of all the stimulators for B cells, 
T cells are proved to be the most efficient drivers for B cells 61. The presence of 
CD8+T cells with memory phenotype has worse prognosis, due to tissue 
damage caused by these cells 62. There is hypo-methylation in the CG- rich 
areas of the genome, and this has been proved by a recent study on identical 
twins. The twins were discordant over manifestation of lupus and the twin with 
active lupus has demonstrated hypo-methylation of the CG rich regions of the 
genome 63. Lupus patient have reduced expression of Treg cells and enhanced 
Th17 cells64.Treg cells suppress immune responses whereas Th17 cells are 
responsible for activation of inflammation by activating the production of IL-
17.There are many mechanisms that have been postulated to establish the role 
of DNA de-methylation in T cells of lupus patients. In lupus patients there is 
increased expression of the protein growth arrest and DNA damage induced 45 
alpha (GAD 45 alpha). This GAD 45 alpha protein is responsible for the 
removal of methyl groups from DNA47. There can be decreased ERK pathway 
signaling due to decreased expression of the protein DNAMT1 protein that 
leads to DNA de-methylation. There are recent documented evidences that T 
cells of lupus patients are characterized by the increased synthesis of ICOS, 
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CXCR5, Bcl6 and also IL-21 that mediate important signal which promotes the 
differentiation of B cells directed against self antigens65,66. PTPN22 acts as 
adapter molecule in B cells of healthy individuals. Studies on risk variant 
PTPN22 in lupus patients shows that there is increased selection of 
autoantibody producing B cells 67. Apart from impaired regulation of T cells in 
SLE patients, impaired regulation of B cells can also lead to development of 
SLE. There is a recent report that proves an association between Vitamin D 
deficiency and the presence of antinuclear antibodies. The activity of both B 
cells and type I interferons are elevated in SLE patients with concomitant 
vitamin D deficiency68. The products of the stromal cells and chemokines are 
responsible for the production of long lived plasma cells. These long lived 
plasma cells act as the sources for anti-Sm and anti-Ro antibodies in SLE 
patients. These patients are also refractory to B cell depletion therapy 69. 
Plasmablasts in the circulation are the primary sources for anti-dsDNA 
antibodies, so anti-B cell therapy proves to be effective among these SLE 
patients 70. 
 
AUTOIMMUNITY IN SLE: 
 Autoantibodies are the mediators of pathology in SLE due to the 
formation immune complexes with the native antigens. Antinuclear antibody 
can be demonstrated in almost all the lupus patients. The antibodies that are 
more specific for SLE are anti-Smith antibody and anti-ds DNA antibodies. A 
peptide that contains only the amino acids 83-119 of the SMD1 protein binds to 
double stranded DNA. This complex will be recognized by T cells and in turn 
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leads to the production of anti-ds DNA antibodies 71,72. The antibodies that are 
not specific for SLE like Anti- Ro, anti- La and anti- SNP antibodies are also 
characteristically seen in the serum of all SLE patients. Autoantibodies can be 
detected in the serum of the patients even before the appearance of clinical 
manifestations. The average time period between the appearance of antibodies 
and the clinical manifestations of the disease varies between five to six years, 
and the specificity of the antigen being targeted will expand as the duration of 
the disease increases73. Anti-C1q antibodies are also specific for SLE, which 
recognize neo-epitopes of C1q that are bound to apoptotic cells74. Each 
antibody in SLE is responsible for a specific manifestation of the disease. For 
instance the anti-Ro antibodies that are derived from maternal circulation in 
SLE affected mothers are responsible for lupus syndrome in neonates. 
 
AUTO-ANTIBODIES RESPONSIBLE FOR VARIOUS CLINICAL 
MANIFESTATIONS IN SLE: 
 Nephritis   : Anti-ds DNA, Anti-Ro, Anti-C1q, Ids16/6, 31  
     and GN2 
 Vasculitis   : Anti-Ro 
 Dermatitis   : Anti-Ro, Anti-dsDNA 
 CNS    : Anti-ribosomal P, Anti-neuronal, Anti- NR2 
 Lymphopenia  : Anti-lymphocyte 
 Hemolysis   : Anti-erythrocyte 
 Thrombocytopenia : Anti-platelet 
 Clotting   : Anti-phospholipid 
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 Fetal loss   : Anti-phospholipid 
 Neonatal lupus  : Anti-Ro 
 Mild disease   : Anti- RNP without other autoantibody except  
     antinuclear antibody 
 
MECHANISM OF TARGET ORGAN DAMAGE: 
 The target organ damage in SLE is due to activation of complements 
and also release of products from phagocytes caused due to deposited immune 
complexes. A recent study has extensively analyzed the renal infiltrating cells 
at various points of the disease. The study has shown that uncontrolled tissue 
repair and organ dysfunction in SLE is due to the differentiation of monocytes 
into a functional phenotype75. IFN-α is a contributor to the development of 
crescents in lupus nephritis 76. 
 
 The target organ damaged can be vascular system. The common 
vascular lesions include peri-arteriolar onion skinning typically seen in spleen, 
micro-angiopathy in several target organs and also dysfunction of endothelial 
cells that are responsible for premature        atherosclerosis. It has been 
postulated that increased type I interferons are responsible for impaired 
vascular repair in lupus patients 77.  The target organ damage in SLE can also 
been due to granulocytes and pro-inflammatory lipids 78. 
 
CLINICAL FEATURES OF SLE: 
 Systemic lupus erythematosus is the disease associated with a wide 
variety of clinical manifestations. The degree of manifestation of each and 
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every symptom also varies. Some patients will have milder disease while in 
others the disease rapidly progress to life threatening illness. 
 
 Criteria for the classification of SLE was proposed by American college 
of Rheumatology (ACR) in 1971, this criteria was revised in 1982 and again 
revised for the second time in 1997 79,80. 
 
TABLE 1: Criteria for SLE: 
SYMPTOM CRITERIA 
1.Malar Rash 
Fixed erythema over the malar eminences that can be flat 
or raised, but typically spare the nasolabial folds 
2. Discoid rash 
Raised patches that are erythematous, and keratotic scales 
are adherent over the patches associated with follicular 
plugging; Older lesion form atrophic scars 
3. Photosensitivity 
Skin rashes pointing to unusual reaction to sunlight, 
based on the history given by the patient or observation 
by physician 
4. Oral ulcers 
Painless oral or nasopharyngeal ulcer being noticed by 
physician 
5. Arthritis 
Non-erosive arthritis typically involves two or more 
peripheral    joints, and there will be associated 
tenderness, swelling or effusion of joints       
6. Serositis 
Pleuritis- history of pleuritic chest pain or rub heard by 
physician or evidence of effusion in pleura OR 
Pericarditis- As documented by an ECG or rub or 
evidence of effusion in pericardium 
7. Renal disorder 
Proteinuria being persistently above 0.5 g/day or above 
3+ if exact quantitation is not performed OR 
Presence of cellular casts  
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8. Neurologic 
disorder 
Seizures—There should not be any offending drugs or 
any metabolic derangements like ketoacidosis or uremia 
or any electrolyte imbalance OR 
Psychosis-- There should not be any offending drugs or 
any metabolic derangements like ketoacidosis or uremia 
or any electrolyte imbalance 
9. Hematologic 
disorder 
Hemolytic anemia, associated with reticulocytosis  OR 
Leukopenia-Count being less than 4,000/mm3 on greater 
than 2 occasions OR 
Lymphopenia OR 
Thrombocytopenia- Platelet count being less than 
100,000/mm3 and there should not be any offending 
drugs 
10. Immunologic 
disorder 
Anti-DNA antibodies OR  
Anti-Sm antibodies OR 
Positive findings for anti-phospholipid antibodies based 
on: 
1. IgG or IgM anti-cardiolipin antibodies are present in 
abnormal levels in serum 
2. Positive lupus anticoagulant, OR 
3. False positive TPI test or FTA-ABS for at least six 
months 
11. Positive 
antinuclear 
antibody 
Abnormal titer of the antibody as detected  by 
immunofluorescence or equivalent assay at any point in 
time but there should not be any offending drugs 
 
 A person must fulfill at least 4 out of the 11 criteria to be classified as 
SLE. The American college of Rheumatology criterion was being developed as 
a means of classifying SLE patients for the purpose of inclusion in 
epidemiological as well as clinical studies. A concerted effort was made 
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recently to further revise the classification criteria, for example, to make lupus 
nephritis a “stand-alone” criterion and/or add a low complement criterion 16. 
 
        Although SLE has variable clinical manifestations the most common 
presenting manifestations were constitutional symptoms like fever, fatigue and 
weight loss, cutaneous and articular manifestations. 
 
TABLE 2:FREQUENCIES OF VARIOUS MANIFESTATINS IN SLE 16 
MANIFESTATON FREQUENCY 
Constitutional symptoms (fever, fatigue, weight loss) 90% - 95% 
Mucocutaneous involvement (malar rash, alopecia, mucosal 
ulcers, discoid lesions etc.) 80%-90% 
Musculoskeletal involvement (arthritis/athralgia, avascular 
necrosis, myositis etc.) 80%-90% 
Serositis(pleuritis, pericarditis, peritonitis) 50%-70% 
Glomerulonephritis 40%- 60% 
Neuropsychiatric involvement 40%- 60% 
Autoimmune cytopenia 20%-30% 
 
VARIOUS MANIFESTATIONS OF SLE: 
Mucocutaneous Involvement: 
            Mucocutaneous involvement is very common in SLE. Mucocutaneous 
involvement can be classified as 
I. Acute cutaneous lupus erythematosus (ACLE) 
II. Subacute cutaneous lupus erythematosus (SCLE) 
III. Chronic cutaneous lupus erythematosus (CCLE) 
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 Patients with SLE typically display more than one type of cutaneous 
manifestations. The hallmark feature of ACLE is butterfly rash in the malar 
region. The butterfly rash is characteristically macular or papular which is seen 
symmetrically over the cheeks or the bridge of nose but there is typical sparing 
of the nasolabial fold. SCLE has characteristic non-scarring photosensitive 
lesions that can be papulosquamous or annular polycyclic lesions. There is a 
typical predilection for back, neck, shoulders and extensor surfaces for SCLE. 
The annular subtype of SCLE is strongly associated with anti-SSA/Ro antibody 
81.CCLE is characterized by a variety of photosensitive lesions that ultimately 
leads to skin atrophy and scarring. The most common sub-type of CCLE is 
discoid lupus which can be a localized or generalized discoid lupus. Discoid 
lesions involving the scalp affects mainly the parietal areas and vertex leading 
to scarring alopecia. Photosensitivity is typical of almost all SLE patients.  
Photo provocation will cause abnormal skin reactions to UVA, UVB and 
visible light in greater than 90% of lupus patients 82. 
 
MUSCULOSKELETAL INVOLVEMENT: 
 Arthritis and arthralgia are the other common clinical manifestations of 
SLE present in up to 90% of the patients during the course of the disease 83. 
Lupus arthritis can involve any joint but characteristically symmetric 
inflammatory arthritis predominantly involves knees, wrists and small joints of 
the hand. Hand deformities occurring as a result of arthritis is called “Jaccoud’s 
like arthropathy” that can even occur over foot. There is also rare co-existence 
of tophaceous gout in SLE,84,85,86. 
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RENAL INVOLVEMENT: 
 Renal involvement is very common in SLE being a significant cause of 
morbidity and mortality. Although more than 90% of the patients present with 
evidence of renal pathology on biopsy only 50% will develop clinically 
diagnostic nephritis and is a cause of significant mortality and morbidity87. 
Laboratory Evaluation for renal pathology: 
 
Urine analysis 
 Urine analysis by microscopy is an essential screening test for 
monitoring of lupus nephritis patients 88. Proteinuria, Hematuria, dysmorphic 
RBCs, red blood cell casts and WBC casts are the features seen in routine urine 
analysis of nephritis patients . Accurate measurement of proteinuria is critical 
because proteinuria is a very critical indicator of glomerular damage. Studies 
indicate that in chronic kidney disease patients, strong predictor GFR decline is 
the magnitude of proteinuria 89. Normal daily protein excretion is less than 150 
mg. The gold standard procedure is to collect 24 hours urine to assess 
proteinuria. Spot protein to creatinine ratio can be also be used to assess 
proteinuria. Spot PCR, although not so accurate as 24 hours timed sample, a 
spot ratio can be a helpful screening test for the detection of proteinuria and is 
useful in differentiating nephrotic from non-nephrotic range proteinuria90. The 
gold standard procedure for proteinuria assessment is PCR in 12 -24 hour 
urine91. 
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 While following up the patients with lupus nephritis, assessment of 
detoriation in renal function over time is more important than absolute value of 
renal function tests. Although easy to measure, serum creatinine is an 
insensitive indicator and trend of serum creatinine over time is the reasonable 
method to follow the renal function in an individual with lupus nephritis. It is 
preferable to use Estimated GFR calculated by Cockraft- Gault formula or 
Modification of diet in renal disease (MDRD) formula. In a SLE patient with 
clinical or laboratory features suggestive of nephritis, a renal biopsy is an 
absolute necessary to confirm the diagnosis and also to assess the degree of 
disease activity. 
 
 The degree of SLE glomerulonephritis is classified by the International 
society of nephrology/ Renal pathology society (ISN/RPS). There are six 
categories of SLE glomerulonephritis based on light microscopy, 
immunofluorescence and electron microscopy findings 92. 
 
Class І :     Minimal mesangial lupus nephritis 
Class ІІ :   Mesangial proliferative nephritis 
Class ІІІ :  Focal lupus nephritis 
Class ІV :  Diffuse lupus nephritis 
Class V :   Membranous lupus nephritis 
Class VІ :  Advanced sclerotic lupus nephritis 
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PLEUROPULMONARY INVOLVEMENT: 
 Pleuritis is seen in nearly 50% of the SLE patients. High levels of serum 
C-reactive protein (CRP) have been found to correlate well with the presence 
of pleuritis and other forms of serositis in SLE provided no other infections are 
present in the patient 93,94. Thus serum CRP provides useful clue for the 
identification of pleuritis in SLE patients. Shrinking lung syndrome occurs in 
small set of lupus patients and should be considered while evaluating a SLE 
patient with unexplained dyspnea and associated pleuritic type of chest pain 95. 
 
CARDIOVASCULAR INVOLVEMENT: 
 The typical cardiovascular manifestations in SLE include pericarditis 
with or without effusion, myocarditis, valvular abnormalities and also coronary 
artery disease. The most common cardiac manifestation seen in SLE is 
pericarditis. Women with SLE have 50 fold increased risk of myocardial 
infarction compared to healthy individuals 96. 
 
NEUROPSYCHIATRIC INVOLVEMENT: 
 Neuropsychiatric lupus (NPSLE) is a broader term that envisages a wide 
range of neurologic and psychiatric manifestations seen in SLE patients. 
NPSLE can involve any aspect of central or peripheral nervous system. CNS 
disorders range from diffuse processes such as acute confusional states, 
psychosis, headache and mood disorders to more focal processes such as 
myelopathy, seizures and chorea. 
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GASTROINTESTINAL INVOLVEMENT: 
 Any part of the gastrointestinal system can be affected in SLE patients. 
Dysphagia is the predominant feature seen in over 13% of the SLE individuals. 
Manometric studies in SLE patients have demonstrated abnormalities in 
esophageal motility 97. Abdominal pain due to peritonitis, pancreatitis, 
mesenteric vasculitis, and intestinal pseudo-obstruction has been noted in 40% 
of SLE patients. 
 
OPHTHALMOLOGIC INVOLVEMENT: 
 Keratoconjunctivitis sicca is the most common ocular manifestation in 
SLE 98. The abnormalities in retina can be detected by ophthalmoscopic 
examination, and the retinal abnormalities appear to correlate well with 
nephritis and CNS manifestations in lupus and also with anti-phospholipid 
antibodies 99. Episcleritis and scleritis can also occur in SLE affected 
individuals. 
 
HEMATOLOGIC MANIFESTATIONS: 
 Hematologic involvement is common in SLE. All the three major blood 
cell lines will be affected in the disease. Anemia of chronic disease is the most 
common etiology for anemia in SLE, but anemia can also be due to 
autoimmune hemolysis or hemolysis due to microangiopathy. Leukopenia 
occurs in approximately 50% of SLE patients. Mild thrombocytopenia can be 
noted in up to 50% of the SLE patients due to autoimmune platelet destruction. 
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Thrombocytopenia in SLE is almost always correlated with antithrombopoietin 
antibodies100 
 
 Lymphadenopathy and Splenomegaly are also the common 
manifestations in SLE.  No individual laboratory test or a clinical manifestation 
is specific for the diagnosis of SLE. Instead, the disease is being diagnosed by 
the constellation of characteristic symptoms, signs and laboratory findings. 
 
SEROLOGICAL MARKERS IN SLE: 
 Serological tests are more important in the diagnosis of SLE patients. 
SLE is characterized by production of wide variety of auto-antibodies that are 
crucial for the diagnosis of SLE 101. The presence of antinuclear antibodies is 
the hallmark serologic feature in the diagnosis of SLE. But positive ANA is 
also seen in other autoimmune disorders like rheumatoid arthritis and Type I 
Diabetes mellitus. Elderly individuals exhibit low titers of ANA even in the 
absence of autoimmune disorders 102 It is necessary to identify the target 
nuclear antigen in the patients with positive ANAs. The prominent antibody 
seen is the Anti-dsDNA which is seen in around sixty percentage of the SLE 
patients. In fact presence of Anti-dsDNA is highly specific for the diagnosis of 
SLE. Anti-Sm antigen similar to anti-dsDNA is also highly specific for the 
diagnosis of SLE, but the antibody is present only in 30% of lupus patients. 
The other antibodies that can be detected in SLE patients include Anti-RNP 
antibodies, cytoplasmic anti-Ro and anti-La antibodies. Unlike anti-dsDNA and 
Anti-Sm antibodies, the sensitivity and specificity of cytoplasmic antibodies 
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are very low. More than 90% of neonates exhibiting lupus manifestations have 
associated anti-Ro antibodies103,104. 15-20% SLE patients have positive 
Rheumatoid factor of anti-IgG variety regardless of the presence of arthritis105. 
Anti- CCP antibodies can also be seen in SLE. The patients with active disease 
have hypocomplementemia, due to complement consumption by the immune 
complexes106,107. SLE affected individuals are also reported to have hereditary 
complement deficiency of complement components C1q, C2 and C4, so 
reduced complement components in SLE is not always reflection of the 
complement consumption.108, 109, 110 The degree of hypocomplementemia and 
titers of anti-ds DNA correlates with disease activity in SLE. There are many 
systemic disorders that mimic SLE. Hence before diagnosis of SLE, a 
comprehensive search of other autoimmune disorders especially an extensive 
genetic study is needed to diagnose SLE. 
 
CTLA-4 PROTEIN 
 Cytotoxic T Lymphocyte associated protein 4 (CD-152), a molecule 
expressed on the surface of helper T cells is a member of the immunoglobulin 
superfamily and is a transmitter of inhibitory signal to T cells. The protein was 
first identified by screening the complementary DNA library of murine T 
cells111 
 
 The genes for CD28 and CTLA-4 are having similar structures112 and 
the cytogenetic location is 2q33.2 (FIGURE 3)  
 
  
 
 
 
 
 
FIGURE 3: CTLA-4 GENE STRUCTURE AND LOCATION: 
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 The gene for CD28 and the gene for CTLA-4 have also been linked at 
the molecular level. Genomic studies have proved that they are found on the 
same artificial chromosome of the yeast bearing human genomic DNA, and 
these two genes are separated from each other only by a distance of 25-150 
kb113. There is approximately 20% homology in base sequence between CD28 
and CTLA-4 genes but there is striking 31% homology in aminoacid sequence 
between CTLA-4 and CD28 protein. This homology of base sequence between 
CTLA-4 and CD28 genes and their close proximal location has led to the 
hypothesis that, the two genes CTLA-4 and CD28 are the products of 
duplication event from a single gene. 
 
The CTLA-4 protein has an 
 An extracellular V shaped domain, 
 A trans-membrane domain and 
 A cytoplasmic domain (FIGURE 4). 
 
 The molecular weight of the protein is 24, 656 Daltons. Alternate 
splicing of CTLA-4 gene will produce a variety of isoforms of CTLA-4 
protein.  
 
The two major isoforms of the protein are the 
 The membrane bound, and 
 The soluble isoform. 
 
  
 
 
FIGURE 4: STRUCTURE OF CTLA-4 PROTEIN 
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 The soluble isoform of CTLA-4 protein is a monomer. The membrane 
bound isoform of the protein is a homo-dimer and the two monomeric units are 
interconnected by a di-sulphide bond.114 
 
 The intracellular domain of CTLA-4 protein is similar to CD28 and has 
no intrinsic catalytic activity. The domain has two different motifs. 
 A YVKM motif and 
 A proline rich motif. 
The YVKM motif is able to bind PI3K, PP2A and SHP-2 and the 
proline- rich motif is able to bind SH3 containing proteins. 
 
FUNCTION OF CTLA-4 PROTEIN: 
 T cell receptors are necessary to identify a wide variety of unknown or 
known pathogens that can attack us from the universe. But some T cell 
receptors are even disadvantageous that they recognize our own antigens, so 
that the entire T cell becomes self-reactive against our own tissues. Thymus 
offers some degree of protection against the generation of self-reactive T cells. 
But the protection offered by the thymus gland is necessarily incomplete and a 
good proportion of self-reactive T cells are able to reach the peripheral 
circulation. In peripheral circulation CTLA-4 protein plays the key role in 
controlling self-reactive T cells. This above fact is being supported by an in-
vitro study which states that, mice genetically deficient in CTLA-4(CTLA-4 
knockout mice) has profound immune dysregulation and autoimmune disease 
115 
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MECHANISM OF ACTION OF CTLA-4 PROTEIN: 
 Treg cells the CD4+ T cells are responsible for suppressing potentially 
deleterious activities of helper T cells, and are the major type of cells 
expressing CTLA-4 marker on their surface116. The CTLA-4 molecule does not 
function in isolation, instead it requires CD28 molecule, the related 
glycoprotein for its active function. (FIGURE 5) Engagement of both TCRs 
and CD28 molecule on the surface of T cells with their respective ligands leads 
to T cell activation. The T cell activation in turn leads to increased surface 
expression of CTLA-4 molecule. The expressed CTLA-4 molecule acts as a 
negative regulator of T cell function117  
 
 There are a variety of mechanisms being proposed by which CTLA-4 
protein cause inhibition of T cell responses 
 
1. CTLA-4 protein binds with greater affinity to B7 family of ligands 
CD80 and CD86 with much higher affinity compared to T cells, so that 
CD 28 mediated T cell activation is dampened. 
2. The localization of CD28 molecule to the cell surface is disrupted by 
CTLA-4 protein. 
3. A series of phosphorylation events in the intracellular domain of CTLA-
4 protein will cause inhibition of T cell function  
 
 SHP-2 and PP2A bonded to intracellular domain of CTLA-4 protein will 
cause de-phosphorylation of proteins such as CD3 and LAT. This CD3 and 
  
 
 
FIGURE 5 
T CELL RECEPTORS AND CO-RECEPTORS ON THE SURFACE OF T 
CELLS: 
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LAT proteins are responsible for transmission of stimulatory signal from T cell 
receptors to interior of the cell. As a result of SHP-2 and PP2A mediated de-
phosphorylation of CD3 and LAT proteins, the signal transmission from T cells 
receptor is blocked leading to the inhibition of T cells (FIGURE 6). In fact a 
more significant and interacting CTLA-4 partner is serine/threonine 
phosphatase PP2A118. Apart from SHP-2 and PP2A, YVKM motif of 
intracellular domain of CTLA-4 protein also binds P13K. But the role played 
by bonding of CTLA-4 protein to P13K in inhibiting T cell responses has not 
yet been elucidated  
 
 CD 28 is the most powerful co-stimulatory molecule discovered so far.  
When T cell receptors alone are stimulated without concomitant activation of 
CD 28 there will not be stimulation of T cells.  This ultimately may land up in 
T cell anergy119. The signals transmitted from both the T cell receptors and 
CD28 will integrate at some point inside the T cell and will activate the genes 
responsible for proliferation of specific T cells.  The CTLA-4 protein by 
directly antagonizing CD-28, controls the excess stimulation of CD-28 
molecules in response to antigenic stimulus. So, in case of CTLA-4 deficiency 
fatal autoimmunity will be observed due to excess stimulation of CD28 
molecule by its ligands CD80/86. This auto-immunity triggered by CTLA-4 
loss can be prevented by deletion of the ligands CD80/86 or CD28, the co-
stimulatory receptor 120,121.   
 
  
 
 
 
FIGURE 6: MECHANISM OF ACTION OF CTLA-4 PROTEIN: 
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 In case of low level expression of CD80/86 molecules, there will not be 
any activation of T cells by APCs. There exists a strong competition between 
CTLA-4 and CD28 molecules for the ligands CD80 and CD86 molecules and 
the strong inhibitory signals from CTLA-4 molecule will overwhelm the weak 
stimulatory signal from CD28 molecule122 
 
ROLE OF CTLA-4 IN THE REGULATION OF T CELL FUNCTION:  
 The figure indicates that antigen with lower level of affinity for TCRs 
cannot activate T cells, because of the strong inhibitory effect from CTLA-4 
protein that overwhelms the weak stimulatory effect of the antigen. On the 
other hand if T cell encounters an antigen with high level of affinity for T cell 
receptors, then full activation of T cells will follow. This is because sustained 
positive signaling from T cell receptor and CD28 will overwhelm the negative 
signaling from CTLA-4. Antigen presenting cells with high level expression of 
CD80 and CD86 molecules can also cause full blown activation of T cells. The 
activation of T cells is followed by increased expression of CTLA-4 protein on 
the surface of T cells. In fact CTLA-4 protein peaks approximately 48-72 hours 
following activation of T cells, so that now CTLA-4 protein mediated signaling 
dominates T cell response leading to inhibition of IL-2 production from T cells 
and so the cell cycle progression comes to a standstill.122 (FIGURE 7) 
 
ROLE OF CTLA-4 PROTEIN IN AUTOIMMUNITY: 
CTLA-4 protein mediated inhibition of T cells is responsible for 
tolerance developed by T cells against the native antigens. Whenever this 
  
 
 
FIGURE 7: CTLA-4 MOLECULE IN THE REGULATION OF T CELL 
FUNCTION: 
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peripheral mechanism of T cell tolerance is eliminated, that is any pathological 
process that leads to inhibition of CTLA-4 function will end result in 
proliferation of T cells against self-antigens and lays the foundation for the 
development of variety of autoimmune disorders123. Hence the in-vivo 
tolerance of T cells to native antigens is due the presence of actively 
functioning CTLA-4 protein. The signal transduced from CTLA-4 molecule 
can potentially inhibit signal from TCR or CD28 or both.  
 
CTLA-4Ig:  
The CTLA-4 molecule has no effect on signal transduction if the 
particular cell lacks CD28 co-stimulatory molecule. This can be proved by 
injection CTLA-4Ig by parenteral route. Anti-CTLA-4 monoclonal antibody 
(CTLA-4Ig) binds to CTLA-4, so that its interaction with CD28 is blocked, 
which is now free to interact with CD80/86, prolonging the cellular activation 
and thus augmenting the immunity mediated by T cells.124 In normal healthy 
individuals as indicated in the figure CTLA-4Ig will cause proliferation of T 
cells by effectively blocking the CTLA-4 mediated inhibitory signals (FIGURE 
8). But the Immunoglobulin directed against CTLA-4 protein has no role on T 
cells if the T cells lack CD28 molecule.  The naive T cell requires some degree 
of TCR stimulation, for CTLA-4 to mediate its inhibitory effect. The absence 
of TCR stimulation is incompatible with life.  
 
  
  
 
 
FIGURE 8: FUNCTION OF CTLA-4Ig 
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CELL SURFACE EXPRESSION OF CTLA-4 MOLECULE: 
CTLA-4 molecule is believed to have restricted expression on the 
surface of CD4 and CD8 T cells, but there is a recent study reporting the 
expression of CTLA-4 molecule on the surface of B cells and Thymocytes 
125,126. It has been proved that similar to CD8, CTLA-4 molecule is a 
homodimer linked by disulphide linkages. But many recent reports have proved 
that CTLA-4 molecule can also exist as a monomer127. Resting T cells will not 
have any surface expression of CTLA-4 molecule. The activation of T cells by 
antigen presenting cells result in up-regulation of CTLA-4 molecule on the 
surface of T cells128, 129. On encountering an antigenic stimulus there occurs the 
T cell activation which is then followed by surface expression of CTLA-4 
molecule which peaks by approximately 48 hours and returns to normal level 
by 96 hours130. CTLA-4 mRNA expression starts within one hour of T cell 
activation by antigenic stimulus131. A more recent report about CTLA-4 protein 
is that, it is found localized inside the intracellular vesicles and will cycle 
between intracellular stores and cell surface depending on the need of the 
cell132. CTLA-4 expression on the cell surface is also mediated by endocytosis 
by clathrin133. The interaction between cytoplasmic domain of CTLA-4 and 
clathrin associated protein AP-2 is responsible for rapid clearance of CTLA-4 
from the cell surface134. FACS analysis shows that activated T cells have much 
higher level of CTLA4 protein than being estimated. The ligands for CTLA-4 
molecule are CD80 and CD86, expressed on the APC which is similar to 
CD28135, 136,137. 
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DIFFERENTIAL AFFINITY BETWEEN CTLA-4 AND CD28 FOR 
LIGANDS 
There is a hexapeptide motif, MYPPPY, in the extracellular domain of 
CTLA-4 molecule, which is also seen in CD28 molecule. This hexapeptide 
motif is responsible for interaction of CTLA-4/CD28 with the ligands CD80 
and CD86138. The CTLA-4 molecule has much higher affinity for the ligands 
compared to CD28.  This increased strength of binding is due to the presence 
of non-conserved residues CDR1-and CDR3-analogous regions in CTLA 4 
molecule138 
 
THE IN-VITRO EVIDENCES FOR CTLA-4 MOLECULE AS A 
NEGATIVE REGULATOR OF T CELLS: 
              Both CTLA-4 and CD28 molecules have extensive homology and are 
restricted only to the surface of T cells, hence grouped together as co-
stimulatory molecules.   Many in vitro experiments have improved our current 
level of understanding of CTLA-4 function and provided strong evidence for 
the negative regulatory role of CTLA-4 molecule over T cell function 
 
 Artificially cross-linking CTLA-4 molecule with its ligands leads to 
inhibition of T cell 
 Artificially cross-linking CTLA-4 molecule with its antibody leads to 
enhanced activation of T cell 
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 Blocking interaction between CTLA-4 molecule and its natural ligands 
CD80/CD86 with neutralizing antibodies will again lead to enhanced 
activation of T cells. 
 CD80mIg is an immunoglobulin fusion protein in which the 
extracellular domain of CD80 is found fused to Fc domain of murine 
Immunoglobulin139. When this immunoglobulin (CD80mIg) is added to 
CTLA-4 molecule, the resultant effect is the blockage of release of IL-3 
from CD 4+ effector T cells 
 
MECHANISM OF CTLA-4 SIGNALING: 
 The elucidation of the mechanism by which CTLA 4 molecule mediates 
its inhibitory effect on T cells is only in the beginning stage.  
 
a) CTLA-4 molecule as a mediator of Apoptosis:       
 CTLA-4 as a mediator of apoptosis has been proposed by several 
studies. T cells on activation by specific antigens leads to increased expression 
of CTLA-4 molecule which in turn leads to apoptosis of activated T cells140. 
 
 Antigen activated T cells will have their CTLA-4 molecule being 
engaged to B7 molecules on the surface of antigen presenting cells. This results 
in the generation of series of signals that ultimately down-regulate the release 
of IL-2 from activated T cells resulting decreased activation of T cells. The 
engagement of CTLA-4 molecule and B7 molecule generates a series of signals 
both in the T cells and the Antigen presenting cells.  
 
  
 
 
FIGURE 9: CTLA-4 MOLECULE AS A MEDIATOR OF APOPTOSIS 
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 Foxo3, a molecule present in the nucleus of antigen presenting cell gets 
activated as a result of interaction between CTLA4 and B7. This Foxo3 
molecule will control the proliferation of T cells by limiting the availability 
of cytokine IL-6 to T cells, which is essential for the survival of these cells. 
T cells exposed to limited Interleukin- 6 has lower survival advantage and 
are more prone to apoptosis. 
 T cells are highly dependent on cytokine IL-2 for survival, Interaction 
between CTLA-4 and B7 results in the inhibition of release of Interleukin -2 
from T cells resulting in clonal deletion of T cells. (FIGURE 9) 
 
b) Non-apoptosis mediated cell signaling by CTLA-4:              
 There are many studies that contrasted the hypothesis that CTLA-4 
molecule mediates apoptosis of T cells. Instead the signal from CTLA-4 
molecule has few major effects on activated T cells 
 Blocks the synthesis and release of Interleukin 2 
 Blocks the expression of Interleukin 2 receptor 
 Blocks the cell cycle progression of activated T cells 141,142. 
 CTLA-4 molecule will recruit a phosphatase to the surface of T cells 
and this phosphatase will in turn inhibit the signal from T cell receptors.  
 Motility of T cells and signals through PI3 kinase can also be modulated 
by CTLA-4,that leads to inhibition of T cells 
 The SH-2 domain of PI-3 kinase and SH-3 domain binds to the 
cytoplasmic region of the CTLA-4 molecule triggering the sequence of 
events that ultimately results in inhibition of T cells. 
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 A recent work has suggested that CTLA-4 molecule will capture and 
remove B7-1 and B7-2 from the membrane of antigen presenting cells, 
making them unavailable to trigger CD-28. 
 
C) Reverse stop signaling model for CTLA-4: 
 T cell motility through normal lymph nodes was studied through multi-
photon microscopy, which gave evidence for reverse stop signaling model143 
.This model proposes that there is reversal of TCR induced stop signal by 
CTLA4 molecule. The stop signal generated by T cell receptor is necessary for 
firm contact between TCR and antigen presenting cells (APC). By reversing 
this stop signal, CTLA-4 molecule mediates reduced interaction between T 
cells and antigen presenting cells. 
 
 Although there were many hypotheses being proposed for the 
mechanism of action of CTLA-4 molecule, the exact sequence of events from 
binding of CTLA-4 molecule and its ligands to the inhibition of T cells still 
remains a maze to be solved. Even before the detection of the surface 
expression of CTLA-4 molecule by flow cytometry, the inhibitory effects of 
CTLA-4 molecule were detected on the T cell.              
 
 The CTLA-4 mediated termination of T cell is responsible for 
prevention of activation induced T cell death as the protein inhibits the over 
activity of T cells in response to antigenic stimuli. CTLA4 molecule by 
preventing antigen induced cell death is responsible for the generation of 
antigen specific memory cells 144. 
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ROLE OF CTLA-4 ANTIBODY: 
 Soluble intact anti-CTLA-4 monoclonal antibody or its F (ab) fragment 
alone has the same role when injected. Both CTLA-4 monoclonal antibody and 
its F(ab) fragment will inhibit the CTLA-4 molecule from interacting with its 
natural ligands CD-80/86. The first study that was conducted to analyze the 
effect anti- CTLA-4 mAb in human has reported that, antigen induced 
expression of T cells will be enhanced by both intact CTLA-4 mAb and its Fab 
fragment 145. CTLA-4 antibody activates both CD4+ T cells as well as CD8+ T 
cells.  
 
The neutralizing antibody can be used therapeutically to enhance the 
action of T cells: 
 There will be will be enhanced expression of CD8+ T cells in response 
to the stimulation by super-antigen of staphylococcus, staphylococcal 
enterotoxin B (SEB) in the presence of CTLA-4 monoclonal antibody 
146.  
 CTLA-4 blockade by monoclonal antibodies in combination with 
melanoma-specific vaccines has been investigated as a potential means 
of treating advanced melanoma147. Ipilimumab and tremelimumab are 
the CTLA-4 monoclonal antibodies with promising antitumor activity in 
patients with advanced melanoma. These monoclonal antibodies acts as 
'immune checkpoint' which interrupts signal mediated by CTLA-4 and 
thus inhibits the inhibitory signal to T cells.148  
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 There are many recent studies which in contrast to older literatures have 
reported that, CTLA-4 protein could inhibit the activation of T cells even if 
CD28 molecule is absent149, 150    
 
SOLUBLE CTLA4 PROTEIN: 
 In the year of 2000, Oak and Hallet first described the alternate 
transcript of the CTLA-4 gene, which lacks the trans-membrane region of the 
native CTLA-4 protein151. This protein is then called by the name soluble 
CTLA-4 protein (sCTLA-4). Subsequently, there are many studies that 
identified the increased expression of the protein in many autoimmune 
disorders like systemic sclerosis, SLE and myasthenia gravis152, 153. sCTLA-4 
mRNA has been reported to be constitutively expressed on non-stimulated T 
cells and its expression is being down-regulated after activation of T cells. But 
the level of sCTLA-4 protein is elevated in the serum of patients with 
autoimmune disorders. The biological significance of such sCTLA-4 elevation 
is that, the protein blocks the interaction of CD80/86 with CD28 thus inhibiting 
the T cell activation in early stages. Also the sCTLA-4 protein in increased 
levels will block the interaction between membrane CTLA-4 with CD80/86 
ligands. This results in reduced inhibitory signals to T cells. This double edged 
nature of sCTLA-4 is responsible for pathogenesis of autoimmune disorders 
 
SOLUBLE vs. MEMBRANE CTLA4 PROTEIN: 
 sCTLA-4 plays a more important role than membrane (m)CTLA-4 in 
the early stage of the immune response. sCTLA-4 is constitutively expressed in 
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plasma, while (m)CTLA-4 is expressed on the surface of T cells only upon 
activation the activation of T cell by APCs.  Also, sCTLA-4 has been shown to 
have immune regulatory properties in vitro. Increased production and 
subsequent secretion of CTLA-4 into the plasma may start in the very early 
phase of the disease. sCTLA-4 may block the interaction between B7 (CD80, 
CD86) on APCs and mCTLA-4 on T cells, thereby interfering with the 
inhibitory signal sent to T cells to enhance the immune response. On the other 
hand, sCTLA-4 may also bind B7 expressed on APCs and thus interfere with 
B7:CD28-mediated co-stimulation of T-cell responses. sCTLA-4 along with 
soluble CD28 plays important roles in modulating the activation of T cells, 
thereby leading to the exacerbation of disease activity 
 
SINGLE NUCLEOTIDE POLYMORPHISM: 
 Single nucleotide polymorphism is the DNA sequence variation 
occurring in only 1% of the population. The DNA sequence variation is such 
that, a single nucleotide differs between the members of a biological species or 
between the paired chromosomes. For example, a single nucleotide 
polymorphism can replace nucleotide cytosine(C) with nucleotide guanine (G) 
within the stretch of DNA. 
 
 On an average a single nucleotide polymorphism can occur once every 
300 nucleotides. So there is possibility of 10 million single nucleotide 
polymorphisms in the entire human genome. There are few SNPs that are 
proved to be associated with the development of disease. SNPs can also predict 
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individual response to certain drugs and their susceptibility to various toxins. 
The SNPs are the focus of intense research recent days, because they help to 
locate the genes that are associated with the development of disease. SNPs 
occurring within a gene or in the promoter region of the gene plays a more 
direct role in disease expression by affecting the expression of the gene. 
 
ARMS PCR: 
              The amplification refractory mutation system, also known as allele 
specific polymerase chain reaction is a simple as well as rapid methodology for 
the detection of single nucleotide polymorphisms. This method was originally 
described by newton et al in 1989154 ARMS is based on the use of sequence 
specific PCR primers that allow amplification of DNA only when target allele 
is present in the sample. So following ARMS PCR the presence or absence of 
PCR products indicate presence or absence of target allele. 155 In Tetra primer 
ARMS PCR, also designated as T-ARMS PCR, has two sets of primers 
 
INNER SET OF PRIMERS 
 Allele specific forward primer 
 Allele specific reverse primer 
 
OUTER SET OF PRIMERS 
 Non allele specific forward primer 
 Non allele specific reverse primer 
 
  
 
FIGURE 10: TETRA PRIMER ARMS PCR 
 
Diagrammatic representation for the tetra-primer ARMS-PCR method for the 
detection of single nucleotide polymorphisms 
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 So in T-ARMS PCR, both the wild type and the rare allele are amplified 
in a single reaction. The outer primer amplifies larger fragment of the target 
irrespective of the allele present. Inner primer combines with the particular 
outer primer to generate allele specific amplicons of different sizes. The 
product can thus be discriminated by gel electrophoresis. (FIGURE 10) 
 
CTLA4 GENE IN SLE: 
 Many candidate gene studies and genome wide association studies have 
thrown light on the genetic contributors to SLE. Apart from this, multiple 
genetic variations play a key role in the development of disease. The common 
theme proposed by all the gene polymorphism studies in relation to SLE is that, 
variation in gene sequence leads to the synthesis of a defective protein that acts 
as a trigger for the development of autoimmunity. CTLA4 is one of the 
candidate genes whose polymorphism results in defective CTLA4 protein and 
so disease development. There are four possible polymorphic sites in CTLA4 
gene that are reported to be associated with SLE. 
 
 Exon 1 +49 (A/G) 
 Promoter -318 (C/T) 
 Promoter -1722 (C/T) 
 3’UTR microsatellite (106-bp allele) 
 
 Fewer studies have also reported the polymorphism in CT 60 (A/G) 
gene promoter region can also favor the development of disease. Out of all the 
above genomic studies exon 1 is so crucial because it is the only coding region 
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of the gene prone for polymorphism, which codes for the functional CTLA 4 
protein. There were extensive research works conducted on this candidate 
genomic site and reported that the presence of G allele at 49th position of the 
first coding region (exon 1) of CTLA4 gene is strongly associated with the 
development of SLE. 
 
  
Aim of the Study 
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AIMS AND OBJECTIVES 
 
The aim of the study is 
 To analyze significance of CTLA-4 gene polymorphism (+49A/G) 
and SLE                                          
 CTLA-4 gene has 4 exons or coding regions. 49th position in 
the first exon is prone to polymorphism in which A, the normal 
allele can be replaced by G, the risk allele, whose significance 
to SLE is the purpose of this study.                    
 To assay the level of soluble fragment CTLA-4 protein and to 
correlate them with the allelic variation 
         The effect of gene polymorphism on the expression of the 
corresponding protein is studied. The level of CTLA-4 protein is 
analyzed among cases and controls and compared between A/A, 
A/G, G/G genotypes.     
  
Materials & Methods 
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MATERIALS AND METHODS 
 
 This is a case-control study approved by Institutional Ethics Committee 
(IEC), Madras Medical College and Rajiv Gandhi Government General 
Hospital. 
 
STUDY POPULATION: 
CASES: 
 Blood sample was collected from 100 proven SLE patients attending 
Rheumatology OPD (Lupus clinic), Madras Medical College, RGGGH. All the 
SLE patients selected for the study have satisfied revised ACR criteria for the 
classification of SLE. 
 
CONTROL: 
 100 unrelated healthy population who were age and sex matched to the 
study population have been chosen as controls. 
 
SAMPLE COLLECTION AND SEPERATION: 
 4 ml of whole blood was being collected in Disodium EDTA tubes. The 
tubes are then subjected to centrifugation at 3000rpm for 15 minutes. Plasma 
being separated is used for the estimation of renal parameters. Plasma is also 
aliquoted and stored at -20  C for the estimation of CTLA-4 protein. After 
separation of plasma, buffy coat was extracted and transferred into a 2 mL 
centrifuge tube. From the Buffy coat further DNA extraction was continued on 
the same day of sample collection. 
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EXTRACTION OF DNA: 
 DNA was extracted from separated buffy coat with the help of pure fast 
human blood genomic DNA Minispin prep Kit 
 
PRINCIPLE 
 The cells are incubated with proteinase K in the presence of a chaotropic 
salt. This results in the lysis of the cells and the released nucleases will also be 
inactivated during this short incubation period. The nucleic acids released from 
the cells will then bind specifically to the special glass fibres pre-packed in the 
spin columns. Bound nucleic acids will then be purified by repeated “wash and 
spin” steps. This will remove any contaminating cellular components. Finally 
low salt elution will release the nucleic acid from the glass fibre. 
 
PROCEDURE: 
 All the DNA Extraction steps were carried out at room temperature 
using a table top micro-centrifuge that can have speed adjusted between 1000-
12000 rpm. 
 
Steps in DNA Extraction: 
 20µL of proteinase K is transferred to a fresh 1.5mL centrifuge tube 
 200µL of whole human blood is transferred to the same centrifuge tube 
and the contents are mixed well by brief vortexing 
 200µL of Lysis buffer is added and the contents of the tube are again 
mixed well by brief vortexing 
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 Incubate the micro-centrifuge tube at 56ºC for 15 minutes 
 After incubation, 200µL of 100% ethanol is added to each of the 
centrifuge tubes and the contents are mixed well by vortexing. 
 After mixing, a brief centrifugation of 1.5ml centrifuge tubes is done. 
This will remove drops from inside the lid. 
 From the 1.5ml centrifuge tube, the whole sample has to pipetted into 
the spin column. 
 The sample in the spin column is then centrifuged at 8000rpm for 1 
minute. The flow through is discarded and the column is again placed 
back in the same collection tube 
 500µL of ethanol mixed wash buffer-1 is then added to the spin column, 
and is centrifuged at 8000rpm for 1 minute. The flow through is 
discarded and the column is again placed in the same collection tube. 
 500µL of ethanol mixed wash buffer-2 is then added to the spin column, 
and is centrifuged at 12,000rpm for 3 minutes. The flow through is 
discarded along with collection tube 
 The spin column is then transferred to a fresh 1.5mL micro centrifuge 
tube 
 100µL of elution buffer is then added to the centre of the spin column 
membrane without touching the membrane with pipette tip 
 The contents are incubated at room temperature for 2 minutes and then 
centrifuged at 8000rpm for 1 minute 
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 The DNA from spin column is now eluted out into the centrifuge tube. 
The centrifuge tube can now be discarded 
 The DNA being separated is stored at -20º C for future use 
 
IDENTIFICATION OF EXTRACTED DNA: 
 The DNA being extracted was identified by agarose gel electrophoresis 
 
PROCEDURE: 
 The agarose to be used for DNA Electrophoresis should be low EEO 
agarose. The DNA after extraction is subjected to electrophoresis and 
visualized under UV trans illuminator. 
 
A proper size tank and tray is selected. 
 0.24g of agarose is weighed and is transferred to an Erlenmeyer flask. 
30mL of TAE buffer (pH-8.3) is then added to agarose. 
 Place the flask in microwave and allow it to boil for 60 seconds 
 Allow the contents to cool for few minutes and then 2µL of Ethidium 
bromide (10mg/mL) is added. 
 After mixing the contents well, agarose is now transferred to a 30mL 
tray with comb in place and the gel is allowed to solidify 
 After the gel has been set, the tray is placed inside the electrophoresis 
tank which is filled with TAE buffer (pH-8.3) (same buffer used for gel 
preparation) 
 Then mix the extracted DNA along with loading dye, Composition-
10mM Tris-HCl (pH 7.6), 0.03% bromophenol blue, 0.03% xylene 
52 
 
cyanol FF, 60% glycerol, 60mM EDTA , (3µL DNA and 2µL Loading 
dye), and load the contents into the well. 
 Power pack is connected to the tank and the constant voltage of  60V is 
applied (7V/cm) 
 The DNA in the sample, along with 1kb ladder is allowed to run for half 
an hour. 
 The bands are then visualized under UV transilluminator  (FIGURE 11) 
 
 From the extracted DNA, the amplification of CTLA4 gene was carried 
out by tetra-primer ARMS PCR methodology. 
 
ARMS PCR: 
 The major advantage of ARMS PCR over conventional PCR is that, the 
procedure apart from amplifying the target gene similar to conventional PCR, 
will also produce different sized products depending on the allelic variation 
present. Thus ARMS PCR is the one step process, in which there is no need for 
further restriction digestion of the amplified products 
 
PRIMERS: 
Primer sequence (5' to 3' direction) 
 Forward inner  primer (G allele-specific) 
5'-AAGGCTCAGCTGAACCTGGATG-3' 
 Reverse inner  primer(A allele specific) 
 5'-AGTGCAGGGCCAGGTCCTTGT-3' 
 Forward outer primer 
  
FIGURE 11 : DNA EXTRACTION PRODUCTS 
 
 
LANE 1:         1 kb DNA LADDER 
LANE 2 to 8:  EXTRACTED DNA 
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          5'-CCAGCCAAGCCAGATTGGAGTTTTA-3' 
 Reverse outer primer 
           5'-CATCCATGGATTGGCTTGTTTTGTTCA-3' 
 
PROCEDURE: 
 Before mixing, all the reagents are thawed completely and then briefly 
centrifuged. The mixing of the reagents is being carried out inside laminar flow 
hood. TABLE 3:The reagents for ARMS PCR are used in the following 
composition. 
 
REAGENT VOLUME 
Red dye master mix 10µL 
A allele specific primer 2.5 µL 
G allele specific primer 2.5 µL 
Purified DNA sample 10µL 
 
The total reaction volume is 25µL.  
 
AMPLIFICATION PROTOCOL FOR ARMS PCR: 
 MyGenie 96 model Bioneer Thermocycler was used to carry out 
amplification of CTLA4 gene 
 
TABLE 4: CONDITIONS FOR PCR: 
 
STEP TIME TEMP 
INITIAL DENATURATION 5min 95ºC 
35 CYCLES 
DENATURATION 30sec 95ºC 
ANNEALING 30sec 58ºC 
EXTENSION 30sec 72ºC 
 FINAL EXTENSION 5min 72ºC 
 
  
FIGURE 12: ARMS PCR PRODUCTS 
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PCR PRODUCTS SIZE: 
Homozygous A/A- 350bp & control 575bp 
Homozygous G/G- 225bp & control 575bp 
Heterozygous A/G- 225bp, 350bp & control 575bp 
 
 The amplified CTLA4 gene products are then visualized under 2.5% 
agarose gel electrophoresis. The Electrophoresis protocol was same as 
explained above except for the concentration of agarose. Entire PCR products 
are loaded into the well and 10µL of 100bp DNA Ladder is used as control 
(FIGURE 12). 
 
Estimation of Human sCTLA-4 protein by ELISA: 
PRINCIPLE 
 Microwell plates are coated with anti-human sCTLA4 antibody. The 
sCTLA-4 protein present in standard or sample binds to antibodies adsorbed to 
the microwell plates. Another anti-human sCTLA-4 antibody which is biotin-
conjugated is then added. This antibody now binds to the human sCTLA-4 
captured by the adsorbed antibody. Wash step removes the unbound biotin-
conjugated anti-human sCTLA-4 antibody. Streptavidin-HRP then added will 
binds to biotin which in-turn is conjugated anti-human sCTLA-4 antibody. 
Again washing will remove unbound Streptavidin-HRP.A substrate solution is 
added to the wells that reacts with horse radish peroxidase. Reaction between 
substrate and enzyme results in the production of colored product, whose 
intensity is proportional to the amount of human sCTLA-4 present in the 
FIGURE 13: ELISA PRINCIPLE 
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sample. The reaction is then terminated by addition of an acid and absorbance 
of the colored product is measured at  the wavelength of 450 nm. A standard 
curve is prepared from 7 human sCTLA-4 standard dilutions. sCTLA-4 protein 
concentration in the sample is then determined. (FIGURE 13) 
 
PREPERATION OF STANDARDS: 
 570µl of distilled water is added to the standard vial provided. The 
concentration of the reconstituted standard is 20 ng/mL 
 
 Take seven test tubes and label: S1, S2, S3, S4, S5, S6, S7. Then 1:2 
serial dilutions of standards are prepared for the standard curve 
 
In the test tube labeled S1, 
 Pipette 225 μl of Sample Diluent into each tube. 
 Pipette 225 μl of reconstituted standard  into the first tube and mix 
 
Concentration of standard 1 = 10 ng/ml 
 Pipette 225 μl of this dilution into the second tube, labeled S2, which 
contains 225 μl of sample diluent. Mix well before the next transfer. 
 
Repeat serial dilutions 5 more times thus creating the points of the standard 
curve 
 Sample Diluent serves as blank(FIGURE 14) 
 
  
  
 
 
 
 
FIGURE 14:PROTOCOL FOR STANDARD DILUTION 
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PROCEDURE: 
 The microwell plates are washed twice with approximately 400 μl of 
Wash Buffer. The plates are washed well with thorough aspiration of 
microwell contents between washes. Wash Buffer is allowed to sit in the 
wells for about 10 – 15 seconds before aspiration. After the last wash 
step, wells are emptied and microwell strips are tapped on an absorbent 
pad so as to remove the excess wash Buffer. 
 Pipette 100 μl in duplicates to the standard wells S1 to S7. 100 μl of 
Sample Diluent is added in duplicate to the blank wells 
 
TABLE 5: CONCENTRATION OF STANDARDS 
Sample 
Well REPLICATE 1 REPLICATE 2 
A Standard 1 (10ng/mL) Standard 1(10ng/mL) 
B Standard 2 (5ng/mL) Standard 2 (5ng/mL) 
C Standard 3 (2.5ng/mL) Standard 3 (2.5ng/mL) 
D Standard 4 (1.25ng/mL) Standard 4 (1.25ng/mL) 
E Standard 5 (0.63ng/mL) Standard 5 (0.63ng/mL) 
F Standard 6 (0.31ng/mL) Standard 6 (0.31ng/mL) 
G Standard 7 (0.16ng/mL) Standard 7 (0.16ng/mL) 
H Blank Blank 
 
 90 μl of Sample Diluent to the sample wells and add 10 μl of each 
sample in duplicate to the sample wells. Biotin-Conjugate is then 
prepared. Add 50 μl of Biotin-Conjugate to all wells. 
57 
 
Cover with an adhesive film and incubate at room temperature (18 to 25°C) for 
2 hours 
 Streptavidin-HRP conjugate is then prepared 
 Remove adhesive film and empty wells. Wash microwell strips 3 times 
 Add 100 μl of diluted Streptavidin-HRP to all wells, including the blank 
wells. 
 
Cover with an adhesive film and incubate at room temperature (18° to 25°C) 
for 1 hour, 
 Remove adhesive film and empty wells. Wash microwell strips 3 times 
 Pipette 100 μl of TMB Substrate Solution to all wells. 
 
 Incubate the microwell strips at room temperature (18° to 25°C) for 
about 10 min. Direct exposure to intense light is avoided. The color 
development on the plate should be monitored and the substrate reaction 
stopped before positive wells are no longer properly recordable. Alternatively 
the color development can be monitored by the ELISA reader at 620 nm. The 
substrate reaction should be stopped as soon as Standard 1 has reached an OD 
of 0.9 – 0.95. 
 
 Stop the enzyme reaction by quickly pipetting 100 μl of Stop Solution 
into each well. 
 The Stop Solution is spread quickly and uniformly throughout the 
microwells to completely inactivate the enzyme. Results must be read 
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immediately after the Stop Solution is added or within one hour if the 
microwell strips are stored at 2 - 8°C in the dark. 
 Read absorbance of each microwell on a ELISA reader using 450 nm as 
the primary wave length and optionally 620 nm as the reference wave 
length 
 
CALCULATION OF RESULTS: 
 A standard curve is drawn by plotting the mean absorbance for each 
standard concentration on the ordinate against the human sCTLA-4 
concentration on the abscissa. A best fit curve through the points of the graph is 
drawn. The samples have been diluted 1:10 (10 μl sample + 90 μl Sample 
Diluent), the concentration read from the instrument is multiplied by the 
dilution factor (x 10). 
 
TABLE 6: STANDARD CONCENTRATION AND O.D. AT 450 nm: 
Standard Concentration of standard(ng/ml) O.D. at 450 nm 
1 10.00 1. 601 
2 5.00 0.759 
3 2.50 0.412 
4 1.25 0.292 
5 0.63 0.142 
6 0.31 0.078 
7 0.16 0.037 
8 0 0.015 
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STANDARD CURVE: 
 
 
ANALYTES 
I. UREA: 
Mode of assay: 
 Fixed time Assay 
Principle: 
 Urea is acted upon by the enzyme urease to release two molecules of 
NH4+. The NH4+ ions will cause reductive amination of α-ketoglutarate to 
glutamate in the presence of the enzyme glutamate dehydrogenase. The 
reaction is coupled to the oxidation of NADH to NAD+. The NADH but not 
NAD+ is able to absorb light of wavelength 340nm.  So the oxidation of NADH 
to NAD+ is accompanied by decrease in OD at 340nm which is proportional to 
the concentration of urea in the solution 
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Urea +2H2O   urease 2 NH4+   + CO32- 
NH4+   + 2- Oxoglutarate + NADH           GDH  L-Glutamate + NAD+  +  H2O  
 
PROCEDURE: 
 The assay is done in robonik semi autoanalyzer of model prietest 
TOUCH. It is the fixed Time assay in which change in absorbance of the 
sample is measured at the interval of 60 seconds. The initial absorbance is 
measured after a lag time of 20 seconds and final absorbance after the kinetic 
interval of 60 seconds. The rate of change in absorbance is measured. The 
concentration is then calculated from the factor. 
 
II. CREATININE: 
Mode of Assay: 
 Fixed Time assay 
Principle: 
 Jaffe’s reaction 
 
 Creatinine reacts with picric acid in alkaline medium to give orange 
yellow color. The absorbance is measured at the wavelength of 505nm which is 
proportional to the concentration of urea in the sample. 
 
Procedure: 
 The assay is done in robonik semi autoanalyzer of model prietest 
TOUCH. It is the fixed Time assay in which change in absorbance of the 
sample is measured at the interval of 60 seconds. The initial absorbance is 
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measured after a lag time of 20 seconds and final absorbance after the kinetic 
interval of 60 seconds. The rate of change in absorbance is measured. Factor 
has been calculated by using standard. The concentration of creatinine in the 
sample is then calculated by multiplying the factor with the sample absorbance. 
 
III. URIC ACID 
Mode of assay: 
 End point assay 
Principle: 
 Trinders method: 
 
Uric acid + O2  +  H2O    Uricase       Allantoin + CO2 + H2O2 
TOOS + 4AAP  + 2H2O2  Peroxidase       Quinoneimine dye + 4H2O 
 
Procedure: 
 The assay is done in robonik semi autoanalyzer of model prietest TOUCH. It 
is the end point assay in which absorbance is measured at the end 5 minutes external 
incubation. The concentration of uric acid in the sample is assayed by multiplying the 
factor with the sample absorbance. 
 
  
Statistical Analysis 
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STATISTICAL ANALYSIS 
 
 Statistical Analysis was done using SPSS software version 20 (p 
Value<0.05 is stastically significant) 
 
1. Age, Sex, BMI, Serum urea, serum creatinine and  uric acid  levels were 
compared between the cases and controls by unpaired student t- test 
2 . Allele frequency was calculated by allele counting 
3 . Hardy Weinberg equilibrium was assessed by chi- square test 
4 . Genotype frequency and allele frequency between cases and controls 
were compared by chi square test 
5 . Odds ratio for G allele distribution among the study population is 
calculated 
6 . Plasma CTLA-4 protein level between cases and controls was compared 
between study groups by unpaired student t- test 
7 . Plasma CTLA-4 protein level for the each of the three  CTLA-4 
genotype (A/A, A/G, G/G) was compared by one way ANOVA 
8. Age of onset of the disease among GG and non-GG genotype 
individuals were compared by student t-test 
  
Results 
  
S.no AGE (years) SEX DM HT BMI UREA (mg/dL)
CREATININE 
(mg/dL)
URIC ACID 
(mg/dL) 
CTLA-4 
PROTEIN 
(ng/mL)
CTLA-4 
GENOTYPE
1 33 F A A 23.38 28 0.9 4.1 77 A/G
2 34 F A A 21.67 36 1.1 3.7 88.9 A/G
3 29 F A A 24.58 46 1 7.7 120.3 G/G
4 37 F A A 29.91 38 0.8 4.5 63.5 A/A
5 26 F A A 31.21 45 1.2 7.8 109.7 G/G
6 28 M A A 20.07 44 1.5 6.7 111.3 G/G
7 53 F P A 23.38 52 1.4 5.5 96 A/G
8 32 F A A 29.12 18 1 7.4 127 G/G
9 18 F A A 18.34 48 2.1 6.3 142.4 G/G
10 34 M A A 22.22 63 1.9 7.7 83.4 A/G
11 46 F P P 25.89 47 1.8 6.2 92.9 A/G
12 37 F A A 27.31 31 1 4.5 89.9 A/G
13 33 F A A 28.72 53 1.1 6.3 89.3 A/G
14 36 M A A 25.91 71 1.6 7.8 88.2 A/G
15 46 F P A 26.33 22 1.2 4.3 77.1 A/G
16 26 F A A 21.87 54 1.5 5.4 106.7 G/G
17 22 F A A 32.89 21 1 3.5 128.3 G/G
18 33 F A A 20.07 52 1.3 5.3 37.8 A/A
19 34 M A A 23.55 46 0.9 6.7 87.2 A/G
20 39 F A A 26.32 30 1.3 4.2 80 A/G
21 39 F A A 27.18 45 1.4 5.1 77.1 A/G
22 37 F A A 20.45 58 1.2 7.1 73.9 A/G
23 52 F P A 22.15 48 1.8 5 45.3 A/A
24 44 M A A 23.39 26 0.6 4.3 79.8 A/G
25 40 F A A 32.19 50 1.6 6.5 87.6 A/G
26 38 F A A 25.32 15 0.4 4.2 83.2 A/G
27 33 F A A 27.19 46 1 7.3 89.8 A/G
28 39 M A A 29.2 25 0.8 5.5 78.3 A/G
29 30 F A A 31.19 55 1.1 7.8 151.1 G/G
30 43 F A P 19.45 47 1.1 5.7 66.8 A/G
31 31 F A A 29.07 52 1.3 7.2 143.4 G/G
32 35 F A A 28.33 36 0.9 4.5 93.9 A/G
33 30 M A A 20.67 49 1.3 7.6 98.3 G/G
34 37 F A A 23.33 47 1.2 5.4 92.2 A/G
35 28 F A A 21.98 55 1.1 7.1 136.2 G/G
36 29 F A A 25.32 53 0.9 6.5 125 G/G
37 34 F A A 30.07 33 0.7 3.4 91.3 A/G
38 33 M A A 29.98 57 0.7 7.1 98.3 A/G
MASTER CHART FOR CASES
39 39 F A A 23.93 53 1.2 5.2 51.2 A/A
40 28 F A A 21.89 27 0.6 3.7 113.2 G/G
41 38 F A A 29.4 52 1.6 6.3 94 A/G
42 40 F A A 28.49 45 1.2 7.1 86.6 A/G
43 48 F P A 27.19 81 2.2 12.1 36.5 A/A
44 25 F A A 25.47 49 1.5 8.3 108.6 G/G
45 36 M A A 32.54 37 1.2 7 86 A/G
46 37 F A A 27.38 50 0.7 5.3 87.2 A/G
47 33 F A A 28.36 53 1.6 4.8 36.5 A/A
48 24 F A A 29.12 49 1.8 5.5 119.8 G/G
49 47 F A A 24.33 56 1.3 6.1 82.3 A/G
50 40 M A A 25.81 21 1 4.3 43.5 A/A
51 31 F A A 25.22 30 1.1 3.8 123.5 G/G
52 32 F A A 26.81 49 0.6 9.1 119.2 G/G
53 45 F A A 23.32 55 1.3 8.4 86.5 A/G
54 28 F A A 29.9 51 1.5 6.5 107.8 G/G
55 36 M A A 25.22 45 1.7 5.4 73.2 A/G
56 30 F A A 32.13 56 1.6 5.5 118.9 G/G
57 39 F A A 31.18 22 0.5 3.2 129.3 A/G
58 45 F A A 29.81 53 1.5 7.1 105.6 A/G
59 53 F P A 26.88 33 0.7 3.3 49.3 A/A
60 38 F A A 23.33 45 0.9 7.5 78.6 A/G
61 37 M A A 20.8 52 0.9 5.3 69.8 A/G
62 32 F A A 21.11 46 1.2 5.1 88.2 A/G
63 35 F A A 22.8 73 3.2 9 85.3 A/G
64 41 F P A 29.91 54 1.3 8.3 80.6 A/G
65 47 M A A 23.39 65 3.5 7.8 89.2 A/G
66 37 F A A 28.86 47 1.1 4.5 49.3 A/A
67 42 F A A 25.45 18 0.8 7.8 83.6 A/G
68 34 F A A 23.32 55 0.9 8.4 84.9 A/G
69 32 F A A 29.01 56 1.2 6.5 123.3 G/G
70 45 F A A 20.84 54 1.3 3.4 42.3 A/A
71 35 M A A 22.66 36 0.7 9.1 86.3 A/G
72 37 F A A 23.44 52 0.8 8.2 82.3 A/G
73 41 F P A 21.78 51 1.2 11.1 88.9 A/G
74 43 F P A 27.89 57 1.7 13.4 36.3 A/A
75 30 F A A 23.98 55 1.6 5.6 129.8 G/G
76 32 M A A 31.12 25 1.1 3.7 136.6 G/G
77 32 F A A 27.63 32 1.4 8.1 149.3 G/G
78 35 F A A 18.12 46 1 4.2 92.3 A/G
79 40 F A A 29.99 52 1.6 5.3 99.8 A/G
80 38 F A A 20.34 48 1.1 6.1 45.3 A/A
81 33 F A A 20.81 42 1 7.2 90.8 A/G
82 42 M A A 22.33 49 1.5 5.9 83.6 A/G
83 34 F A A 28.45 27 0.8 3.8 82.3 A/G
84 29 F A A 20.06 55 1.4 7.8 128.3 G/G
85 20 F A A 21.82 30 0.9 4.5 106.5 G/G
86 33 M A A 23.33 52 0.8 7.5 84.3 A/G
87 19 F A A 20.92 57 1.3 5.4 98.3 G/G
88 44 F P A 20.84 51 1.3 8.3 83.2 A/G
89 39 F A A 20.32 47 1.2 5.9 57.2 A/A
90 27 F A A 29.98 62 2.1 15.1 99.3 G/G
91 15 F A A 20.1 49 1.3 8.2 101.6 G/G
92 29 F A A 19.2 17 0.5 5.1 108.5 G/G
93 31 F A A 29.3 54 1.1 6.2 130.2 G/G
94 31 F A A 18.16 23 0.8 5.6 103.8 G/G
95 46 F P P 23.39 46 0.9 9.2 86.2 A/G
96 37 M A A 20.25 45 0.8 8.6 80 A/G
97 39 F P A 23.95 35 0.5 3.4 89.2 A/G
98 54 F P P 19.82 53 1.3 5.7 39.8 A/A
99 37 F A A 29.43 52 1.1 4.8 76.5 A/G
100 33 F A A 26.67 51 1 10 92.3 A/G
P- PRESENT A- ABSENT
S.NO
AGE 
(years)
SEX DM HT BMI
UREA 
(mg/dL)
CREATININE 
(mg/dL)
URIC ACID 
(mg/dL) 
CTLA-4 
PROTEIN 
(ng/mL)
CTLA-4 
GENOTYPE
1 31 F A A 28.59 22 0.8 4.4 29.8 A/A
2 16 F A A 22.31 16 0.4 3.1 40.6 A/G
3 26 M A A 23.5 29 0.7 4.5 33.8 A/A
4 36 F A A 26.3 31 1 5.2 63.8 G/G
5 30 F A A 31.9 25 0.9 5 22.3 A/A
6 51 F P A 25.54 28 1.1 6.2 28.4 A/A
7 39 F A A 20.12 30 0.6 2.3 31.8 A/A
8 43 F P A 23.33 17 1.1 3.5 54.9 A/G
9 38 M A A 33.56 27 0.8 4 40.2 A/A
10 32 F A A 31.11 27 1.2 2.6 56.3 A/G
11 34 F A A 27.33 18 1 5.3 23.4 A/A
12 37 F A A 25.56 22 0.9 2.4 48.3 A/G
13 35 F A A 31.56 33 1.1 2.7 52.8 A/G
14 45 F P A 34.66 24 0.6 4.2 66.5 A/G
15 37 F A A 21.11 35 0.8 6.8 78.5 G/G
16 33 M A A 32.25 13 1.2 4.3 43.6 A/G
17 22 F A A 27.11 21 1 3.7 39.8 A/A
18 34 F A A 21.34 32 1.1 4.7 28.6 A/A
19 33 F A A 23.98 45 1.4 5.3 73.4 G/G
20 39 F A A 30.09 30 0.8 4.1 51.6 A/G
21 33 F A A 25.57 22 0.9 3.7 53.4 A/G
22 47 F P A 32.12 19 0.6 3.6 30.3 A/A
23 37 M A A 23.88 21 1 5.1 52.8 A/G
24 39 F A A 22.13 37 1.4 6.3 28.3 A/A
25 36 F A A 20.45 43 1.5 7.1 30.6 A/A
26 32 F A A 23.62 26 1 3.3 45.8 A/G
27 45 F P A 28.78 25 0.9 4.1 43.9 A/G
28 40 M A A 26.55 17 0.9 3 26.5 A/A
29 37 M A A 25.47 30 0.5 2.2 28.3 A/A
30 35 F A A 20.01 31 1.3 5.7 40.8 A/G
31 30 F A A 20.98 27 1.1 4.3 46.7 A/G
MASTER CHART FOR CONTROLS
32 43 F A A 21.22 32 0.8 3.8 25.5 A/A
33 30 F A A 31.1 24 1.2 3.4 53.3 A/G
34 39 F A A 19.33 19 0.7 4.1 21 A/A
35 33 M A A 24.58 25 0.6 4.3 63.8 A/A
36 48 F P P 29.98 36 1.2 6.1 48.9 A/G
37 39 F A A 32.13 26 1.4 5.5 46.3 A/G
38 35 F A A 26.47 30 1 4.3 44.3 A/G
39 37 F A A 29.14 16 0.8 5.2 27.7 A/A
40 31 F A A 20.78 22 0.5 3.3 25.6 A/A
41 35 M A A 23.22 18 0.9 4.7 43.4 A/G
42 15 F A A 20.01 25 1.2 4.5 42.8 A/G
43 42 M P A 25.11 38 1.3 3.6 31.1 A/A
44 37 F A A 28.96 33 0.6 5.1 49.8 A/G
45 30 F A A 21.11 21 1.1 4.2 72.8 G/G
46 52 F P P 33.36 27 1.1 4.9 39.8 A/G
47 27 F A A 24.57 36 0.9 3.2 26.7 A/A
48 29 M A A 22.78 24 1.2 2.9 81.3 G/G
49 28 F A A 28.9 17 1.3 2.1 48.9 A/G
50 36 F A A 23.78 28 0.9 4.5 23.5 A/A
51 31 F A A 21.93 21 0.6 4.3 52.3 A/G
52 26 F A A 34.19 30 0.4 5.1 36.5 A/A
53 38 M A A 29.19 27 1 5.4 72.8 G/G
54 29 F A A 26.12 19 0.9 6.4 66.5 G/G
55 39 F A A 28.23 17 1.3 3.2 22.3 A/A
56 33 F A A 29.45 37 1.3 3.3 43.5 A/G
57 41 M A A 21.78 23 0.8 5.6 22.3 A/A
58 37 F A A 25.09 21 0.5 3.2 53.6 A/G
59 21 F A A 23.47 30 0.9 4.5 48.9 A/G
60 23 F A A 21.7 48 1.4 8.9 46.6 A/G
61 38 F A A 32.79 36 1.1 2.2 27.3 A/A
62 34 F A A 18.65 22 0.7 5.5 45.9 A/G
63 46 M P A 19.99 26 0.6 5.6 28.6 A/A
64 35 M A A 21.78 19 1.1 4.3 25.5 A/A
65 39 F A A 34.43 25 0.7 4.8 46.6 A/G
66 50 F P A 29.9 30 0.8 2.3 43.3 A/G
67 37 F A A 31.78 21 1 6.1 52.3 A/G
68 33 F A A 28.7 33 1.1 4.5 52.3 A/G
69 17 M A A 23.89 18 0.9 3.9 68.3 G/G
70 35 F A A 25.74 27 0.8 4.3 23.6 A/A
71 46 F P P 27.02 21 0.8 3.2 45.6 A/G
72 30 F A A 27.92 23 1.2 4.4 29.1 A/A
73 37 F A A 21.84 39 1.4 5.7 46.3 A/G
74 34 F A A 31.92 30 0.6 5.4 52.3 A/G
75 28 M A A 26.18 22 0.6 7.2 51.5 A/G
76 31 F A A 23.33 17 1.1 4.3 29.8 A/A
77 31 M A A 26.77 21 0.9 5.1 26.4 A/A
78 29 F A A 25.54 19 0.9 3.8 27.5 A/A
79 35 F A A 29.87 25 0.4 3 62.3 A/G
80 41 F A A 20.73 23 1.3 4.1 49.8 A/A
81 37 M A A 21.01 38 1.2 7.3 45.6 G/G
82 41 F A A 28.91 26 0.8 2.1 27.5 A/A
83 30 F A A 31.19 33 1 5.9 33.9 A/A
84 34 F A A 32.66 25 1.3 3.2 93.8 A/G
85 28 F A A 21.49 15 0.9 3.4 47.5 A/A
86 35 F A A 27.94 28 1.1 6.2 27.8 A/A
87 32 M A A 20.81 30 0.6 5.4 48.9 A/G
88 31 F A A 22.94 18 0.4 3.4 18.9 A/A
89 39 F A A 23.97 21 0.8 4.5 64.5 A/A
90 48 F P A 21.11 39 0.9 5.5 94.8 A/G
91 23 F A A 29.84 20 0.5 3.2 18.8 A/G
92 33 M A A 31.1 16 1 2.4 49.3 A/G
93 38 F A A 28.88 37 1.2 2 56.8 A/G
94 29 F A A 19.1 27 0.5 4.5 29.8 A/A
95 36 F A A 23.34 31 0.7 3.8 48.5 A/G
96 40 M A A 20.17 16 0.7 3.3 36.3 A/G
97 38 F A A 32.12 23 1.1 6.4 26.5 A/A
98 39 F A A 26.11 36 1 5.4 46.8 A/G
99 28 F A A 25.39 27 0.8 3.2 88.9 G/G
100 32 F A A 24.1 49 1.5 8.5 28.3 A/A
P-PRESENT A-ABSENT
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RESULTS 
 
MASTER CHART 1 & 2: 
 The Age, Sex, BMI, Serum urea/ creatinine/ uric acid level, Plasma 
CTLA-4 protein levels and Genotype of 100 SLE cases and control population 
were tabulated in Master chart 1and 2. 
 
 The Age/sex/BMI of the study population is tabulated to assess the 
comparability of the two study groups 
 Serum urea/ creatinine and uric acid level were analyzed between cases 
and controls to assess the effect of disease on the blood parameters 
 CTLA-4 genotype and CTLA-4 protein levels were assessed between 
cases and controls, so that it is possible to assess the effect of gene 
polymorphism over corresponding protein level as well as disease 
manifestation 
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COMPARISON OF VARIABLES BETWEEN CASE AND CONTROL 
POPULATION 
 The table shows that two groups, cases and controls were age & sex 
matched, and levels of urea, creatinine and uric acid were significantly higher 
in SLE patients compared to control population 
 
Table 1 
VARIABLE PATIENTS (N=100) 
CONTROLS 
(N=100) p-VALUE 
AGE 35.57± 7.47 34.83±7.02 0.47- NS 
SEX (M/F) 18/82 21/79 0.592- NS 
DM/HT   (P/A) 17/83 15/85 NS 
BMI 25.18± 3.89 25.99± 4.29 0.164-NS 
UREA (mg/dL) 45.25±12.92 26.45±7.54 P value  <0.001** 
CREATININE 
(mg/dL) 1.2±0.48 0.93±0.27 P value  <0.001** 
URIC 
ACID(mg/dL) 6.3±2.13 4.4±1.39 P value  <0.001** 
 
M- Male, F- Female, DM- Diabetes mellitus,  
HT- Hypertension, P- Present, A- Absent 
DM (P value = 0.831), HT (P value = 0.70) 
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TEST FOR HARDY WEINBERG EQUILIBRIUM: 
 By applying Hardy Weinberg principle, the expected allele frequency is 
calculated.  
 Frequency of A allele = 0.54 
 Frequency of G allele = 0.46 
 
 Then expected genotype frequency according to Hardy Weinberg 
principle is then calculated. Chi square test is performed, using observed 
genotype frequency and expected frequency calculated by HWE. 
 
Table 2 
 
GENOTYPE EXPECTED OBSERVED p- Value 
A/A 58.32 57 
Chi square = 
0.54 
P =0.7 
A/G 99.36 102 
G/G 42.32 41 
 
 Statistical Analysis proves that the genotype distribution is in Hardy 
Weinberg Equilibrium. 
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DISTRIBUTION OF CTLA-4 GENOTYPE AMONG CASES AND 
CONTROLS 
Table 3 
Genotype Control (100) Case (100) P Value 
A/A 43 14 Chi square = 
26.13 
P value  <0.001** 
A/G 47 55 
G/G 10 31 
 
 The type of CTLA-4 gene among cases and controls was analyzed. The 
expected frequency of distribution of each of the three genotypes (A/A, A/G, 
G/G) for cases and controls was then calculated. The significance of difference 
between the above expected frequency and observed frequency for each of the 
genotypes was then computed by chi square test.   
Chi square – 26.13 
P value <0.001** 
 
 Statistical analysis proves that there is higher distribution of A/A 
genotype among healthy population and G/G genotype has higher distribution 
among SLE patients.  
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ALLELE DISTRIBUTION AMONG CASES AND CONTROLS 
 
Table 4 
Genotype Control (100) Case (100) P value 
G+ 57 86 chi square =20.63, 
P value  <0.001** G- 43 14 
 
 The allele frequency of the cases and controls was computed using allele 
counting (Observed frequency). The expected frequency of G+ and G- allele 
for study and control population was then calculated. The significance of 
difference between expected frequency and observed frequency of alleles 
among the study population was then computed by chi square test 
Chi square = 20.63 
P value <0.001** 
 Statistical analysis proves that there is significantly higher distribution 
of G allele among cases compared to the control population. 
 
  
0
20
40
60
80
100
Control (100) Case (100)
57
86
43
14
ALLELE 
FREQUENCY
ALLELE FREQUENCY AMONG STUDY 
GROUPS
G+
G-
68 
 
 
UNIVARIATE ANALYSIS  
 
Table 5 
ALLELE CASES CONTROLS Odds ratio 
G+ 86 57 4.63 
(95% CI-  
2.33 to 9.23) G- 14 43 
 
   Univariate analysis is done to assess the risk for the development of SLE 
if ‘G’ allele (single variable) is present. Odds ratio which is the measure of 
exposure and out-come proves that, there is 4.63 times (95% CI – 2.33 to 9.23) 
increased risk of SLE for the individuals with G allele instead of normal A 
allele at the 49th position of the exon 1 of CTLA-4 gene 
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LEVELS OF CTLA-4 PROTEIN BETWEEN CASES AND CONTROLS 
Table 6 
ANALYTE CONTROLS CASES p-Value 
sCTLA-4 protein 43.85±16.90 91.1± 26.45 <0.001** 
 
 The level of soluble fragment of CTLA-4 protein in plasma was 
compared between cases and controls by unpaired t test. There is significantly 
higher level of sCTLA4 protein levels among cases compared to that of control 
population (P value <0.001**) 
 
CONCENTRATION OF sCTLA4 PROTEIN 
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RELATIONSHIP BETWEEN sCTLA-4 PROTEIN LEVELS AND 
GENOTYPE 
Table 7: 
GENOTYPE sCTLA-4 PROTEIN LEVEL (ng/mL) p-Value 
GG 108.24± 25.54 
 
<0.001** AG 68.82± 19.88 
AA 34.39± 11.14 
 
 There is significantly higher level of sCTLA-4 protein level among 
individuals with GG genotype compared to those with AA and AG genotype (P 
value <0.001**) 
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RELATIONSHIP BETWEEN GENOTYPE AND THE ONSET OF 
DISEASE: 
Table 8: 
Genotype GG Non-GG p-VALUE 
Age of onset of 
disease 27.51±4.53 38.9±5.13 <0.001** 
 
 The mean age of onset of disease among the individuals with GG 
genotype is 27.51 years whereas patients with non-GG (A/A &A/G) genotype 
has mean age of onset of 38.9 years. SLE patients with GG Genotype has 
comparatively younger age of onset of disease compared to the patients of non-
GG (A/A and A/G) genotype. (P value <0.001**) 
 
AGE OF ONSET OF SLE AMONG THE GENOTYPES: 
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Table 9 : MULTIPLE LOGISTIC REGRESSION ANALYSIS: 
Observed 
Predicted 
Allele 
G- G+ Percentage Correct 
Allele G- 4 10 28.6 
 G+ 2 84 97.7  
Table 10 
INDEPENDENT 
VARIABLES B S.E Wald Df Sig. Expo (B) 
95% C.I. 
LO
W
ER
 
U
PP
ER
 
AGE -.153 .068 5.106 1 .024 .858 .751 .980 
SEX -1.13 1.199 .877 1 .349 .325 .031 3.413 
DM .290 1.096 .070 1 .791 1.337 .156 11.450 
HT -1.388 1.511 .844 1 .358 .249 .013 4.823 
BMI .055 .095 .339 1 .560 1.057 .877 1.273 
UREA -.054 .044 1.541 1 .214 .947 .870 1.032 
CREATININE .168 .865 0.38 1 .846 1.183 .217 6.443 
URIC ACID .293 .224 1.707 1 .191 1.340 .864 2.079 
CONSTANT 11.060 6.265 3.117 1 .078 63581.128   
 
 Binary Multiple logistic regression analysis is performed. The effect of  
independent variables on the dependent variable is analyzed. The independent 
varibles are tabulated above and the dependant variable is presence or absence 
of the disease. Those with G allele has 97.7% risk compared to those without G 
allele who have only 28.6% risk. Multiple logistic regression analysis proves 
the ‘G’ allele is an independent risk factor (except for the age) for the 
development of the disease. Hence presence of ‘G’ allele is an major risk factor 
for SLE. 
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                                                    ROC CURVE 
 
Table 11 
 
Area 
Standard 
Error (a) 
Asymptomatic 
Sig. (b) 
Asymptomatic 95% 
Confidence                
Interval 
.950 .015 .000 .920 .979 
 
 The test result variable: CTLA-4 Protein (ng/ml)  
 The cut- off value of sCTLA-4 protein is 40.4ng/ml. The sensitivity is 
97.9% and specificity is   77.2% .     
  
Table 12: Sensitivity and 1-specificity at different concentrations of 
sCTLA-4 protein in ng/ml 
 
Positive if Greater Than or Equal To(a) Sensitivity 1 - Specificity 
17.800 1.000 1.000 
18.850 .993 1.000 
19.950 .993 .982 
21.650 .993 .965 
22.850 .993 .912 
23.450 .993 .895 
23.550 .993 .877 
24.550 .993 .860 
25.550 .993 .825 
26.000 .993 .807 
26.450 .993 .789 
26.600 .993 .754 
27.000 .993 .737 
27.400 .993 .719 
27.600 .993 .684 
27.750 .993 .667 
28.050 .993 .649 
28.350 .993 .596 
28.500 .993 .579 
28.850 .993 .544 
29.450 .993 .526 
30.050 .993 .474 
30.450 .993 .456 
30.850 .993 .439 
31.450 .993 .421 
32.800 .993 .404 
33.850 .993 .386 
35.100 .993 .368 
36.400 .986 .351 
37.150 .986 .298 
38.800 .986 .281 
40.000 .979 .246 
40.400 .979 .228 
40.700 .972 .228 
41.550 .965 .228 
42.550 .965 .211 
43.050 .958 .211 
43.350 .951 .211 
Positive if Greater Than or Equal To(a) Sensitivity 1 - Specificity 
43.450 .944 .211 
43.550 .937 .193 
43.750 .930 .193 
44.100 .923 .193 
44.800 .916 .193 
45.450 .916 .158 
45.700 .902 .158 
45.850 .895 .158 
46.100 .888 .158 
46.450 .874 .158 
46.650 .860 .158 
46.750 .853 .158 
47.150 .846 .158 
47.900 .846 .140 
48.400 .839 .140 
48.700 .832 .140 
49.100 .804 .140 
49.550 .797 .105 
50.500 .790 .088 
51.350 .790 .070 
51.550 .783 .070 
51.950 .776 .070 
52.550 .748 .070 
53.050 .734 .070 
53.350 .727 .070 
53.500 .720 .070 
54.250 .713 .070 
55.600 .706 .070 
56.550 .699 .070 
57.000 .692 .070 
59.750 .692 .053 
62.900 .685 .053 
63.650 .685 .035 
64.150 .678 .018 
65.500 .678 .000 
66.650 .664 .000 
67.550 .657 .000 
69.050 .650 .000 
71.300 .643 .000 
73.000 .629 .000 
73.300 .622 .000 
73.650 .615 .000 
Positive if Greater Than or Equal To(a) Sensitivity 1 - Specificity 
75.200 .608 .000 
76.750 .601 .000 
77.050 .594 .000 
77.700 .580 .000 
78.400 .573 .000 
78.550 .566 .000 
79.200 .559 .000 
79.900 .552 .000 
80.300 .538 .000 
80.950 .531 .000 
81.800 .524 .000 
82.750 .503 .000 
83.300 .490 .000 
83.500 .483 .000 
83.950 .469 .000 
84.600 .462 .000 
85.100 .455 .000 
85.650 .448 .000 
86.100 .441 .000 
86.250 .434 .000 
86.400 .427 .000 
86.550 .420 .000 
86.900 .413 .000 
87.400 .399 .000 
87.900 .392 .000 
88.550 .378 .000 
89.050 .357 .000 
89.250 .343 .000 
89.550 .336 .000 
89.850 .329 .000 
90.350 .322 .000 
91.050 .315 .000 
91.750 .308 .000 
92.250 .301 .000 
92.600 .287 .000 
93.350 .280 .000 
93.850 .273 .000 
93.950 .266 .000 
94.400 .259 .000 
95.400 .252 .000 
97.150 .245 .000 
98.800 .224 .000 
Positive if Greater Than or Equal To(a) Sensitivity 1 - Specificity 
99.550 .217 .000 
100.700 .210 .000 
102.700 .203 .000 
104.700 .196 .000 
106.050 .189 .000 
106.600 .182 .000 
107.250 .175 .000 
108.150 .168 .000 
108.550 .161 .000 
109.150 .154 .000 
110.500 .147 .000 
112.250 .140 .000 
116.050 .133 .000 
119.050 .126 .000 
119.500 .119 .000 
120.050 .112 .000 
121.800 .105 .000 
123.400 .098 .000 
124.250 .091 .000 
126.000 .084 .000 
127.650 .077 .000 
128.800 .063 .000 
129.550 .056 .000 
130.000 .049 .000 
133.200 .042 .000 
136.400 .035 .000 
139.500 .028 .000 
 
 The best cut-off  that maximize sensitivity and specificity is 40.4ng/ml. 
At this level sensitivity is .979 and specificity is .772 (1-specificity is .228) 
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DISCUSSION 
 
 SLE is associated with a wide range of clinical and biochemical 
parameters and the disease have a recurrent – remittent course. But, few 
patients have disease with very severe course and the mortality rate is also very 
high. Most common causes of death are renal disease, cardiovascular disease 
and infections. Most SLE patients develop cardiovascular disease at a younger 
age and develop an attack of MI before the age of 50 years, thus increasing the 
rate of SLE associated mortality. Despite the invention of many new therapies 
for the disease and resultant improvement in survival of the patient, the 
mortality rate for SLE is still high. The increased morbidity/mortality 
recommends detailed investigations for still unrecognized etiologies (genetic or 
environmental) that are the putative factors responsible for increasing 
morbidity and mortality in SLE.    
 
 This is a candidate gene study that deals with how variation in CTLA-4 
gene results in expression of the disease. The functional relevance of CTLA-4 
gene to the disease is that, CTLA-4 gene polymorphism results in uncontrolled 
proliferation of self-reactive T cells, paving the path for autoimmunity in SLE.     
 
 The presence of G allele at 49th position (codon 17) in exon 1 of CTLA 
4 gene will code for the aminoacid alanine, whereas A allele at the same locus 
will code for threonine 156. Thus polymorphism of the gene results in altered 
expression of the gene which alters the primary structure of CTLA-4 protein in 
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the leader peptide sequence. This alteration will then affect the intracellular 
trafficking of CTLA-4 protein. The surface expression of CTLA-4 protein gets 
reduced associated with elevated plasma levels of soluble fragment of the 
protein. The reduced surface expression of the inhibitory protein results in 
enhanced activity of the T cells against the native antigens. 
 
 Statistical analysis proves that A allele is common in healthy population 
and G allele in those with disease (chi square =20.63, p-Value< 0.001**). The 
individuals with GG genotype has significantly increased risk of SLE 
compared AG and AA (Chi square = 26.13, p < 0.001**). There is significantly 
elevated level of soluble fragment of CTLA-4 protein (p<0.001**) in the 
plasma of SLE patients compared to that of controls and the individuals with 
GG genotype have significantly elevated levels of sCTLA4 protein level 
(p<0.001**) in plasma and compared to AA and GA genotype.  
 
 Liu et al157 studied the expression of CTLA-4 molecules on the surface 
of activated T cells by flow cytometric analysis and reported that, in 
polymorphism, although there is normal expression of CTLA-4 protein on the 
surface of quiescent T cells, there will be weaker expression of CTLA-4 in 
response to antigenic stimulus thus supporting the present study. 
 
 The study by Ueda et al158 also correlated with the present study.  Ueda 
et al has reported that the common allelic variation is associated with lower 
mRNA levels of the soluble alternative splice form of CTLA4 in patients with 
autoimmune disease 
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 The study contrasts with the study by parks et al159. Parks et al analyzed 
all the potential sites of polymorphism in CTLA-4 gene and reported that there 
is no significant relationship between polymorphism in CTLA-4 gene and 
occurrence of SLE.  
 
 Pullmann et al160 in 1999 indicated that the “non-MHC linked CTLA-4 
gene could confer susceptibility in SLE, as it does in various other autoimmune 
diseases like Hashimoto thyroiditis, Graves' disease and IDDM.” The study 
done by Ahmed et al161 in 2001 has concluded that “CTLA‐4 gene appears to 
play a significant role in the development of SLE in the Japanese population”. 
Maurer et al162 in 2002 has stated that “G allele at position +49 of exon 1 
affects the CTLA4-driven down-regulation of T-cell activation and may be an 
important factor in the pathogenesis of autoimmune diseases”. All these studies 
points strongly towards the correlation between gene polymorphism and SLE. 
 
 Previous epidemiological studies have proved that SLE is more common 
among Asians163,164 and the clinical severity of the disease will also be worse. 
So it is crucial to identify the putative risk factor, which make Asians high risk 
population.  
 
 Barreto et al165, Heward et al166, Aguliar et al167 Ulker et al168 
independently investigated the GG genotype distribution among Portugal, 
England, Spain and Turkish population respectively. The GG genotype 
distribution among the four populations was around 10% among SLE affected 
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individuals and 8.5 to8.8% among healthy population. Ahmed et al reported 
that there was 48% and 31% distribution of GG genotype among SLE patients 
and healthy controls. The present study identifies 31% distribution of GG 
genotype among cases and 10% among controls. These data suggest there is 
higher frequency of GG genotype among Asian population compared to 
European population, which might be one of the possible reasons that place 
Asians as high risk population.           
 
 Sugimoto et al169 in 2008 has suggested that GG genotype at 49th 
position of exon 1 of CTLA-4 gene is associated with earlier onset of SLE in 
two Japanese families. The present study also correlates with the study by 
Sugimoto et al. The mean age of onset of SLE in those with non-GG genotype 
is 38.9 years and those with GG genotype has younger age of onset of disease 
(mean=27.5 years). Hence the individuals with GG genotype have earlier onset 
of SLE.  
 
 The study proves that individuals with GG and AG genotype have 
increased risk for SLE, compared to those with AA genotype, confirming the 
fact that ‘G’ allele is associated with increased risk for the development of this 
autoimmune condition. There will be altered expression of the gene associated 
with polymorphism, altering the intracellular trafficking. The reduced 
expression of CTLA-4 protein on the surface of T cells result in reduced 
negative regulation on T cells, resulting T cells becomes active against self-
antigens. 
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CONCLUSION 
 
The conclusions arrived by the present study are 
1. CTLA-4 gene polymorphism (+49 A/G) is associated with the 
development of SLE. 
CTlA-4 gene has 4 exons, the polymorphism in exon 1 of the gene at 
49th position in which A allele if replaced by G allele will increase 
the risk of SLE. There is higher distribution of G/G and A/G 
genotype among cases compared to controls. 
2. G allele in fact is the independent risk factor for the development of 
disease 
The individuals with risk allele (G allele) have 4.6 times increased 
risk of    SLE. 
3. There will be elevated level of soluble fragment of CTLA-4 protein in 
plasma of SLE patients and those with risk allele (G allele) have higher 
level of sCTLA-4 protein compared to those with non-risk allele (A allele). 
4. The patients with GG genotype has comparatively younger age of onset 
of SLE, than those of non-GG SLE patients. 
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LIMITATIONS OF THE STUDY 
 
 SLE is a multifactorial disease that multiple genetic factors along with 
environmental exposure makes the person susceptible prey for this 
autoimmune condition. The study analyzes the effect only a single genetic 
variation that accounts only a smaller percentage to the occurrence of 
disease. The study does not take into account other genetic alterations 
and environmental factors that in combination leads to the occurrence 
of the disease. 
  
 SNP study has multiple implications. 
1. SNP helps in diagnosis of a clinical condition 
2. SNP studies help to assess the severity and prognosis of the disease 
among individual patients 
3. The response of the patients to therapy can be assessed by studying 
the genetic variation among individuals 
 
 The study takes into account only the effect of gene polymorphism on 
the occurrence of disease. The severity and prognosis of the disease in 
polymorphism and the response of individuals with polymorphism to drug 
therapy are not scope of the current study. 
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FUTURE SCOPE OF THE STUDY 
 
 Identification of SNP in CTLA4 gene among families, contributes to the 
earlier identification of susceptible individuals to SLE. Regular monitoring 
of those susceptible individuals helps in earlier diagnosis as well as earlier 
therapy so as to prevent later complications. 
 The study proves that soluble fragment of CTLA-4 protein is elevated in 
SLE patients irrespective of disease activity, hence 
a) sCTLA-4 protein can be used as novel surrogate marker 
of SLE 
b) Antibodies to sCTLA-4 protein can be used as therapy for 
SLE 
 The strength of association between CTLA-4 gene polymorphism and 
severity & prognosis of the disease can be assessed 
 The effective response of the patients with CTLA-4 gene polymorphism to 
therapy and effect of therapy on the levels of sCTLA-4 protein can be 
assessed. 
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ஆராvசியாள ைகெயா~ப                      பuேகபாள ைகெயா~ப   
ேததி:  
  
CLINICAL PROFORMA 
 
PATIENT DETAILS: 
 Name:                                     Age:                                                         Sex: 
 
Occupation: 
 
Address: 
 
Phone number: 
 
Hospital number: 
 
COMPLAINTS: 
 H/O Skin lesions 
 H/O Photosensitivity 
 H/O Oral ulcers 
 H/O Joint pain 
 H/O chest pain/dyspnea 
 H/O facial puffiness/swelling of legs 
 H/O Seizures 
 H/O altered behavior 
 Relevant past History: 
  Family History: 
  Treatment History: 
  
  
  
CLINICAL EXAMINATION: 
Pulse                                                BP: 
RR: 
GENERAL EXAMINATION: 
CVS: 
RS: 
P/A: 
CNS: 
 
INVESTIGATIONS: 
 Blood Urea 
 Serum Creatinine 
 Serum Uric Acid 
 Assay of sCTLA-4 protein 
 CTLA-4 gene polymorphism analysis. 
